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Purpose/Aims: For adult participants who have received or are receiving treatment for
hematologic and solid tumor malignancies given orally, this study describes the
relationship between participants’ experience of financial toxicity (FT), the participants’
perception of distress associated with FT, and participants’ self-identified adherence to
prescribed treatments in the context of FT.

Background: FT has emerged as an additional source of distress for cancer patients. The
costs of treatments given orally can be prohibitively expensive for patients. Therefore,
these patients may experience considerable distress and may not adhere to treatments as
prescribed.

Method: Descriptive cross-sectional correlational design study of a sample of adult
cancer patients treated with therapy given orally. Study data was analyzed using
descriptive and bivariate correlation statistics.

Findings: Data from 136 participants included participant perceptions of FT, distress and
adherence at seven days and six months post start of treatment. At both timepoints,
patients had moderate scores for FT, according to COST instrument data. At both
timepoints for distress, 39-42% of patients had high distress scores related to FT. There
was no correlation between FT and distress. Responding to specific COST instrument
questions, 80% or participants responded that they feel they have no choice about the cost
of care. At seven days post start of treatment, 67.1% of patients reported that OOP
expenses were higher than anticipated. At six months post start of treatment 59.4% of
patients reported that OOP expenses were higher than anticipated. Most correlations
among variables were weak with the exception of a strong correlation between help from
pharmaceutical companies/foundations and percentage of financial help from those
funding sources (r = .869, p = <.001). Based on data from this sample, FT was not
established as a predictor of distress or adherence to treatment.

Implications for Nursing: Despite this sample data showing minimal statistically
significant correlations, FT has clinical significance. Nurses can mitigate the impact of
FT on patients and caregivers by including FT assessment as a component of clinical
assessment, referring patients to healthcare FT experts and resources and providing
patients and families with support to alleviate FT as a patient stress.
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CHAPTER 1
BACKGROUND and SIGNIFICANCE
Introduction
By the year 2026, healthcare spending is expected to account for more than 19%
of the U.S. economy (Health and Human Services, 2018). And from 2019 estimates,
healthcare spending is expected to top $4.3 trillion (Schnipper et al., 2016). For the
consumer of healthcare, the pace of yearly healthcare costs is increasing at a steady clip,
yet has slowed somewhat in the last few years. For the period 1990-2007, the cost of
healthcare increased on average 7.3% yearly. For the period 2017-2026, healthcare
spending is expected to increase on average 5.5% a year (HHS, 2018). This rise in
healthcare costs can, in part, be attributable to an aging population—the primary
consumer of healthcare—and the rise in the cost of prescription and specialty drugs that
include prescription (non-generic) medications, newly FDA-approved and early in their
patent period. Therefore, prescription and specialty drugs are more costly than generic or
standard formulary medications (Bradley et al., 2016; Shih et al., 2015; Davidoff et al.,
2013).
Contributing to increased healthcare costs, the rise in prescription drugs is
expected to increase 6.3% yearly (HHS, 2018). With the high cost of healthcare, thirdparty private and government health care insurers have transferred more of the burden for
healthcare costs to patients, specifically through co-payments, deductibles and any out of
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pocket (OOP) costs not covered by the insurer (Galbraith et al., 2011). Yet those with
coverage are the lucky ones who at least have some type of healthcare insurance coverage
despite the limitations of that coverage that increase expenses to the patient (Gaba et al.,
2016; Guy et al., 2013; Guy et al., 2014).
Further, the expense of annual insurance deductibles for health plans has been
steadily rising (Claxton et al., 2015). On average in 2017, covered workers contributed
18% of the premium for single coverage and 31% of the premium for family coverage.
Since 2012, family coverage premiums have increased 19%. Since 2007, family coverage
premiums have increased by 55%. (Kaiser Family Foundation, 2017). A study by the
Kaiser Family Foundation reported only 53% of respondents had household incomes that
could cover an annual deductible of $2,400. And when choosing a less robust insurance
plan with a higher deductible of $5,000 annually, only 45% of respondents could afford
that expense (Claxton et al., 2015).
Moreover, for those in treatment for cancer, OOP costs can exceed $5,000
annually (Bernard, Farr, & Fang, 2011; Davidoff et al., 2016). Significantly, the annual
medical cost of cancer care was estimated to be $124.6 billion in 2010 and is projected to
increase to $157.8 billion by 2020 (Mariotto et al., 2011).
In the context of burgeoning healthcare costs, the concept of financial toxicity
(FT) has emerged, especially for those diagnosed with cancer (IOM, 2013; Tucker-Seeley
et al., 2016). FT can be defined as a constellation of financial challenges for patients.
These can include high medical payments during or after treatment ends as well as lower
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income due to job interruption or job loss due to treatment (Zafar & Abernethy, 2013a;
Delgado-Guey et al., 2015).
The Commonwealth Fund has estimated that 23% of insured adults have OOP
healthcare costs that are equivalent to more than 10% of their household income (Ell et
al., 2008). In 2013, a Medicare Current Beneficiary Survey estimated that 28% of cancer
survivors reported high OOP expenses compared to 16% with no cancer history
(Davidoff et al., 2013). Moreover, individuals covered by public insurance report high
proportional OOP expenses, especially when those individuals cannot work due to
illness.
In a 2014 report, the Center for Diseases Control (CDC) estimated annual
healthcare expenses and related productivity losses for male survivors of cancer to be
$4,187, an estimated $1,459 more than those without a history of cancer. For female
survivors of cancer, FT had sustaining effects with their estimated annual healthcare
expenses and related productivity loss at $3,293 compared to those without a history of
cancer, estimated at $1,330 (Ekwueme et al., 2014). In a 2016 Medical Expenditure Panel
Survey of 1,202 cancer survivors, an average 20.4% of these survivors reported financial
hardship associated with their cancer or treatment and extended period of recovery. From
this sample of patients, 7.1% reported borrowing to pay their bills or go into debt, and
almost 12% of patients reported they were unable to cover their OOP costs and that led to
psychosocial hardship (Yabroff et al., 2016).
Therefore, the concept of FT and its impact on cancer patients has gained
visibility and parity with other treatment side effects that require management (ASCO,
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2018; Delgado-Guey et al., 2015). FT, as an unwanted side effect from cancer treatment,
has been shown to affect cancer patients in treatment with similar distress as other side
effects or toxicities from cancer treatment such as fatigue, nausea and vomiting, anxiety
and sleep disturbance (Bestvina et al., 2014; Delgado-Guay et al., 2015; Ubel et al.,
2013). A study of 300 cancer patients in treatment reported that 39% of them experienced
greater financial burden from their care than they expected and 19% stated they were
overwhelmed due to financial distress (Chino et al., 2017). According to a systematic
review of studies about cancer patients and financial distress, an estimated 28-73% of
cancer survivors report FT (Gordon et al., 2017).
Cancer Care: Advances in Treatments
This is a time of breakthroughs in the treatment of cancer, which include the
promise of molecular and genetic-based treatments for those diagnosed with hematologic
or solid tumor malignancies. As additions to multi-modality approaches to treat cancer,
these new therapies are advancing the number of treatment options available to patients.
These treatments can further refine the precision of prescribed treatments since they are
based on the patient’s own genetic and metabolic profile (Haslem et al., 2018). In part
due to these breakthrough treatments, in the U.S. cancer continues to be one of the most
expensive and difficult health challenges to treat (Bradley et al., 2016; Andrews, 2015).
Treatments for cancer have included surgery, radiation therapy, chemotherapy
and biologics therapies, either alone or in combination (Shih et al., 2015; Nair & Kong,
2018). With the addition of targeted therapies—many of them formulated in an oral
form—some cancer patients can take a pill to treat their cancer rather than the
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operationally-complex treatments of surgery, radiation or infusion chemotherapies
(Haslem et al., 2018: Nair & Kong, 2018). Moreover, advances in molecular biology and
genetics have expanded these cancer treatment options given orally, with these treatments
becoming a frequent source of FT (Bayer et al., 2017; Ginex et al., 2017). Although such
targeted treatments given orally have been shown to be more effective and easier to
tolerate (Garraway et al., 2013), OOP copayment costs to the patient can be staggering,
even when insurance pays a large component of the treatment cost (McNulty & Khera
2015; Meisenberg, 2015).
Cancer Treatment and Cost
Targeted therapies in oral form, developed from extensive and often prolonged
clinical trials by pharmaceutical companies and academic facilities, can be very
expensive. A 1995-2013 analysis of 58 approved anticancer drugs reported that adjusted
for inflation, the costs of these drugs increased annually by 10% or approximately $8,500
a year (Howard et al., 2015). Mariotto and colleagues estimated that by 2020, the cost of
cancer care in the U.S. that includes these pricey cancer treatments will be almost $158
billion (using models that account for incidence, survival and cost). This is a 27%
increase over estimates of the cost of cancer care from 2010 (Mariotto et al., 2011).
Even if a third-party payor provides coverage of these treatments and supportive
therapies, the OOP cost to the patient can be steep (ASCO, 2018). In a 2017 analysis of
insurance coverage, 57% of employees with single (non-family) coverage by employersupported insurance had an annual OOP maximum of more than $3,000. And another
18% had an OOP maximum of more than $6,000 (KFF, 2017). And patients may not
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know the OOP cost of these treatments until well after treatment starts since the amount
of the OOP costs for these treatments can vary depending on insurance coverage, facility
discounts with the medication manufacturer and/or pharmaceutical or patient advocacy
assistance programs (Zafar et al., 2103a, 2013b; Zafar et al., 2013c; Zafar, 2016;
Henrikson, & Shankaran, 2016).
In addition, studies show that oncologists are reluctant to bring up the cost of
medications with patients due to a variety of factors, such as not knowing the cost of the
medication themselves, limited data on the clinical value (outcomes based on quality of
life and survivorship), and the patients themselves not wanting to know the cost
(Gidwani-Marszowski et al., 2018; Carrera et al., 2018; Tucker-Seeley & Yabroff, 2016).
In June 2017 in a position statement, the American Society of Clinical Oncology
(ASCO), the professional organization for clinical oncologists, expressed concern about
the affordability of oncology specialty drugs due to unaffordable coinsurance rates and
their OOP expense to the patient (ASCO, 2017).
The costs of receiving care for cancer extend beyond the OOP costs associated
with prescription drugs or co-pays. These costs add up. The extra costs of care include a
constellation of expenses that are in addition to treatment costs. The cost of receiving
care for cancer includes costs of transportation to and from clinic appointments and
treatments, parking fees, hotel stays, over the counter medications, child care while in
treatment, the cost of non-covered second opinions, special diets and other needs.
Especially for low-income patients, transportation issues are a focus of FT and a primary
stressor (Massa et al., 2018; Carrera et al., 2018).
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Moreover, studies estimate that a range of 25-40% of cancer patients are more
likely to miss work or require reduced work hours while in treatment or recovering from
declining health (Ferrell et al., 2018; Huntington et al., 2015; Jagsi et al., 2014). A 2017
systematic review of studies about cancer survivors reported some form of financial
distress because of the patients’ cancer treatment. Studies included in the review reported
that survivors’ mean annual productivity loss was $380-$8,236, with 12-62% reporting
that treatment caused them to be in debt (Altice et al., 2017). A study of cancer patients in
Washington State reported the bankruptcy risk for the general cancer population at 2.1%
approximately 2.5 years after cancer diagnosis (Ramsey et al., 2013).
Financial Toxicity
In cancer care, the objective and subjective financial consequences of cancer
treatment may include significant OOP costs, loss of income, and caregiver burden. Since
2011, the term financial toxicity also has been associated with patients diagnosed with
cancer who face financial challenges related to precision medicine treatments (Carrera,
2017; Zhang, Hueser, & Hernandez, 2017). FT is considered akin to hair loss or nausea
from cancer treatment given the distress that patients feel as a result of experiencing
financial burden (Carrera et al., 2018). Yet the concept of FT as it relates to patients with
cancer is not fully understood (Altice et al., 2017; Gordon et al., 2017). FT as a clinical
concept lacks standard strategies to screen and measure (Carrera et al., 2018; Gilbert et
al., 2017). And the ability to pay, especially when related to life-saving treatment, is a
very personal and individual challenge (Gidwani-Marszowski et al., 2018; Guy et al.,
2015). These financially-impacted choices can affect when and whether an individual
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agrees to treatment, the impact of medical expenses on household finances and the impact
of cancer and treatment on the individual’s quality of life (McNulty & Khera., 2015; Kale
& Carroll, 2016).
Sequelae of Financial Toxicity
In cancer care, with the cost and initial lack of transparency for these OOP costs
to patients, the care team needs to address and better manage FT (Doyle, 2017). The
effects of FT create an additional layer of distress for the patient during a time when the
cancer patient should focus on treatment and management of functional and emotional
side effects. For the patient, FT-related distress can manifest itself as depression and
anxiety (Zafar & Abernethy, 2013a, 2013b; 2016; Perrone, et al., 2016). FT has also been
suggested as a contributing factor to patients not adhering to a costly cancer treatment
regimen given orally.
Due to the high OOP costs, some patients just cannot afford the full cost of the
treatment or decide to partially take the prescribed treatment so they can attempt to
benefit from some of the treatment effects (Bestvina et al., 2014; Wheeler et al., 2018).
Few studies have focused on FT as a factor in care delivery--its effect on the patient’s
adherence to treatment and the wellbeing of patients and their caregivers when patients
are treated (Bestvina et al., 2014; Kale & Carroll, 2016).
Study Purpose, Aims and Hypotheses
For adult participants who have received or are receiving treatment for
hematologic and solid tumor malignancies given orally, this study will describe the
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relationship between participants’ experience of financial toxicity (FT), the participants’
perception of distress associated with FT, and participants’ self-identified adherence to
prescribed treatments in the context of FT.
The aims of this study are:
1.

To describe sociodemographic, clinical and financial characteristics, the

experience of FT, perception of the level of distress, and adherence to treatment in a
sample of adult participants who have received or are receiving treatment given orally for
hematologic or solid tumor malignancies.
2.

To describe relationships between participant sociodemographic, clinical

and financial characteristics, participants’ experience of FT, participants’ perception of
distress, and participants’ adherence to treatment.
Hypotheses:
•

Participant experience of FT will be related to participant perception of distress
while controlling for statistically significant demographic, financial and clinical
characteristic covariates.

•

Participant experience of FT will be related to participant adherence to the
treatment given orally, while controlling for statistically significant demographic,
financial and clinical characteristic covariates.
3.

To explore the likelihood that participant experience of FT predicts

participant perception of distress and non-adherence to the treatment given orally.
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Hypotheses:
•

The participant experience of FT predicts the likelihood of participant perception
of the level of distress.

•

Participant experience of FT predicts the likelihood of participant nonadherence
to the treatment given orally.

Content of this Dissertation: Overview of Chapters
As a foundation for this study, Chapter 1 has introduced the concepts of FT as a
source of distress for cancer patients prescribed treatment given orally. The costs of
treatments given orally can be prohibitively expensive for patients. Therefore, patients
may experience distress and may not adhere to the treatments as prescribed.
Chapter 2 reviews and critiques peer-reviewed literature about FT associated with
cancer patients receiving therapies orally, patient perception of distress related to FT and
adherence related to FT.
Chapter 3 describes the study methods, including the study design, a description
of the population, protection of human subjects, procedures for recruiting patients, data
collection procedures, and the plan for statistical analysis.
Chapter 4 presents the study results organized in order of the study aims.
Chapter 5 discusses the study findings in the context of clinical practice,
implications for practice, future research and policy implications.
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CHAPTER II
CONCEPTUAL FRAMEWORK
and
REVIEW of the LITERATURE
Introduction
For patients receiving treatment for hematologic and solid tumor malignancies
given orally, the purpose of this study is to determine the relationships between the
patient experience of financial toxicity (FT), patient perception of distress, adherence to
prescribed treatments and OOP costs of prescribed treatments. This chapter begins with a
review of the conceptual framework underpinning this study: Carrera’s Conceptual
Framework of Financial Toxicity in the Treatment of Patients with Cancer (Carrera,
2017; Kantarjian, & Binder, 2018). The chapter continues with a review of the literature
as a foundation for the study and specifically addresses cancer treatments given orally,
the cost of those treatments, cancer treatment and distress, and components of FT for
patients in treatment for cancer. Finally, the chapter provides a gap analysis, based on the
literature review, which supports this study’s purpose and aims.
Conceptual Framework
The concept of FT has been referred to in the medical literature since 2001. Its
attributes include a subjective and objective response by cancer patients to the cost of
their cancer therapies. That response is considered a “hardship” or source of “distress”
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due to the financial burden that impacts patients, who are already dealing with the impact
of a cancer diagnoses on their lives (Carrera et al., 2018).
The research conceptual framework for this study is the Conceptual Framework
of Financial Toxicity in the Treatment of Patients with Cancer, which is adapted from
Carrera’s work on the topic (Carrera, 2017; Carrera et al., 2018). The Framework
presents a foundation for FT, created by a back and forth platform that flows among the
patient’s expenditures, wealth, anxiety and discomfort. That platform leads to the
patient’s objective financial burdens, such as the direct costs of treatment and
expenditures associated with treatment. Examples of the patient’s subjective financial
burdens are the patient’s perception and experience of financial distress, resulting in
worry and anxiety about decreased household income and savings (Carrera, 2017;
Carrera et al., 2018).
The conceptual framework, Financial Toxicity in the Treatment of Patients with
Cancer, is shown in Figure 2-1. Evidence to support the interrelated components of the
conceptual framework actually begins with early studies about FT by Zafar and
colleagues, and later studies led by Carrera and Schnipper (Carrera et al., 2018;
Schnipper et al., 2016). Zafar and colleagues were the first to publish about FT affecting
patients’ adherence to treatment. They also proposed strategies to better approach
patients’ experience of FT that included having frank and open discussions among
patients and for health care professionals to take a broader perspective toward treatment
decisions that go beyond strict clinical guidelines (Zafar, 2016; Zafar & Abernethy
2013a; Zafar et al., 2013).
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Figure 2-1
Conceptual Framework of Financial Toxicity in the Treatment of Patients with Cancer
(Used with Permission, John Wiley and Sons: from Carrera et al., 2018)

Based on clinical experience and studies to date, Carrera and colleagues suggest
that the relationship of costs, expenditures and anxiety are on a continuum, increasing
discomfort for the patient. They suggest that this level of patient discomfort merits
effective multidisciplinary approaches to address FT as a toxicity from treatment, just as
more familiar clinically-based toxicities require attention (Carrera, 2017; Carrera et al.,
2018).
Addressing the assessment of value of cancer treatment options, Schnipper and
colleagues have published trailblazing work on behalf of the American Society of
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Clinical Oncologists addressing FT in clinical care. This ongoing work discusses FT
based on value assessment, objective and subjective distress, and shared decision-making
(Schnipper et al., 2015).
As represented in this conceptual framework, FT can be associated with the cost
of newer cancer therapies and with the cost of the therapies (OOP copays and larger
deductibles), which are more the burden of the patient rather than the insurer (Gordon et
al., 2017; Altice et al., 2017; Claxton, Rae & Panchal, 2015).
Therefore, for this study, this conceptual framework suggests relationships
between the patient’s experience of FT and patient perception of distress (subjective
burden). Based on that FT/distress relationship, the framework also serves as a
foundation for FT-associating patient perception of distress (subjective financial distress)
and/or patient adherence to prescribed medication (result of objective financial burden).
Review of Literature
The literature review was based on peer-reviewed articles, published in English
from 2010-2018, that were retrieved from these databases: PubMed, CINAHL, OVID and
Google Scholar. The literature search included the words and phrases, financial distress,
financial toxicity, patient distress, treatment adherence, cancer oral drugs, cancer
treatments, oncolytics, cost of cancer care, oral cancer drug prices and OOP cost of
cancer care. In addition, the reference list of articles was reviewed for further pertinent
resources. Approximately 165 articles were reviewed. The review included studies
primarily of adult patients in the United States.
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Cancer Therapies Given Orally
This is a period of promising cancer treatment made possible by advances in
molecular biology, bioinformatics, pharmacometrics and genetic and genomicengineering (Maeda & Khatami, 2018). Development of new molecular/genomic
treatment strategies has been advancing over the past 40 years, with the first Federal
Drug Administration (FDA)-approved monoclonal antibody treatments for cancer first
introduced into practice settings in 2000-2005 (Brassil & Ginex, 2018; Bayer et al.,
2017).
FDA-approved applications for these immunotherapies or so-called targeted
therapies administered orally have continued at a steady clip, with almost 40 treatments
approved as of 2018. The rate of these FDA approvals continues with new targeted
therapies or applications added to therapy options every few months. To support their
FDA approval, these new treatments given orally must show effectiveness as alternative
treatment strategies, as additional options to treat frail patients or treatments for those
who have exhausted standard treatment options (Shih et al., 2015). Additional
applications for targeted therapies include more advanced-stage hematologic
malignancies and more and later-stage solid tumor malignancies (Nair & Kong, 2018;
Shih et al., 2015).
Targeted therapies given orally include monoclonal antibodies, cytokine
therapies, immune checkpoint inhibitors, oncolytic viral therapies and targeted therapies
(Brassil & Ginex, 2018; Garraway, Verweij & Ballman, 2013). They contribute to the
future platform for cancer treatment termed precision medicine. These treatments, using a
scientific development platform called transformational medicine, target the molecular
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level of cancer cells themselves with specificity to an individual patient’s malignancy,
rather than reverting to a standard, broad, systematic approach to treatment. The staple of
standard systemic treatments continues to be chemotherapy or chemotherapy-radiation
therapy combination treatment protocols (Haslem, Chakaraty & Fulde, 2018; Nair et al.,
2018).
In addition to precision-medicine treatments given orally, oral formulations of
supportive therapy—prescribed to lessen or manage treatment side effects—also continue
to advance in their development. Examples of these supportive therapies include growth
factors that reduce cancer treatment-prompted neutropenia (reduced white and red blood
cell effectiveness and production), anti-nausea and vomiting agents and antiinflammatory agents (Irwin & Johnson, 2015).
Cost of Therapies: Oral Administration
Insurance coverage of these prescribed oral medications is based upon the
classification of the pharmaceutical therapy into one of three categories: brand, generic
and specialty (Hoadley et al., 2015a, 2015b). A brand name medication is a medication
developed by a pharmaceutical company that holds the patent for the medication and, as
such, possesses exclusive rights to the manufacturing and sale of the medication. Once a
patent expires, other companies can produce copies of brand-name drugs, known as
generic medications, that have the same dosage, intended use, effects, side effects, route
of administration, risks, safety, and strength as the original drug. Because generic drugs
are not exclusive to a single manufacturer, they are usually less expensive. A specialty
medication is a high-cost prescription therapy prescribed to treat complex, chronic
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conditions (FDA, 2018). Most cancer treatments given orally, sometimes called
oncologics, are considered specialty medications. Usually, these specialty medications
are not included in the formulary of the insurance carrier and as such may not be
considered a covered medication by the insurer (Hoadley et al., 2015b). In some cases,
the cost or partial cost of a specialty medication can be covered if the prescriber provides
clinical justification for the therapy. Whether a specialty medication is a covered benefit
by the insurer is based on the insurer’s policies, guidelines and discussion with medical
experts (Carrera et al., 2018; Schnipper et al., 2016).
Overall, the cost of these oral cancer therapies is exceedingly high. For example,
in 2015, the annual cost of the oncologic ponatinib, a treatment for chronic myeloid
leukemia (CML), was an estimated $138,000. As of 2015, the cost of induction (initial)
treatment for chronic lymphocytic leukemia (CLL) with omacetaxine is $28,000 per year,
followed by $14,000 annually for maintenance doses. The cost of another oncologic
agent given orally, bosutinib, is $118,000 per year (McNulty and Khera, 2015). CLL
treatment and management is expected to outpace other cancer diagnoses in its costs.
Figure 2 lists FDA-approved medications as of 2018 given orally as treatment for
malignancies and their monthly cost (Carrerra et al., 2018).
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Figure 2-2 (reproduced Table)
(Used with Permission, John Wiley and Sons: from Carrera et al., 2018)

Since 2010, the FDA has approved more specialty drugs than standard therapy
drugs for the treatment of cancer. Specialty drugs are estimated to account for 25% of
drug spending and constitute one of the largest expenditures for employee health benefit
plans (Business Group Health, 2018). The costs of these drugs are projected to increase at
a rate of at least 10% per year, which is probably an unrealistically low estimate
(Dusetzina et al., 2014). Specialty pharmacies that focus on the distribution of these drugs
have recently emerged to take advantage of these expensive and lucrative medications,
even though only 4% of patients are treated with specialty medications (Business Group
Health, 2018).
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The Patient’s Out of Pocket (OOP) Costs
Cancer treatments have rarely been affordable without insurance coverage, but
insurance coverage in the past has been robust enough to cover most of the costs of
traditional, standard treatment (Soni, 2016; Bradley et al., 2016; Shih et al., 2015).
Specialty medications, however, are usually not covered under the patient’s prescription
drug benefit. Coverage of these medications is not like that of intravenous treatments,
which are often administered in an in-patient or out-patient setting, and as such, are
covered under most insurer’s medical benefit plans (KFF, 2018). Now with these new,
promising treatments being given orally, the cost to patients can be significant with an
increased share of the cost of treatment shifting to the patient (Schnipper et al., 2016;
Shih et al., 2015; Morrison, 2015).
As an example, the tyrosine kinase inhibitor imatinib was introduced in 2001 as a
first-line treatment for CLL. By 2012, the cost of treatment was approximately
$92,000/year (Dusetzina et al., 2014). In 2015, depending on a patient’s insurance
coverage and the insurer’s policies about specialty medication coverage, the OOP cost of
imatinib for patients could be nearly $700 per month for 58 months (Shanafelt et al.,
2015). In another estimated calculation about the OOP cost of imatinib in 2014, the
annualized OOP costs were estimated at $8359 (Kantarjian et al., 2014). Since 2015,
additional second-generation tyrosine kinase inhibitors have become treatment options
for CLL. Yet the yearly cost of these second-generation therapies has climbed to more
than $100,000, accompanied by a higher range of OOP costs to the patient (Dusetzina et
al., 2014).
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Some estimates have these OOP costs as much as ten times higher than OOP costs
for other medications partially covered on the insurer’s formulary (Hoadley et al.,
2015b). OOP costs can escalate based on whether the price of the medication is based on
classification as generic or brand drug and whether the medication is on the insurer’s
formulary as a covered medication (Rotenstein, Dusetzina & Keating, 2018). Moreover,
the increase in cost-sharing for more expensive oral specialty drugs has escalated from
3% in 2004 to an estimated 25% in 2013 (Meisenberg 2015). Further, Davidoff and
colleagues estimated that 50 % of Medicare beneficiaries with a cancer diagnosis spend
at least 10% of their income on OOP costs of their cancer treatment (Davidoff et al.,
2013).
The Medicare Donut Hole
Most Medicare patients participate in Medicare Part D, a prescription drug
benefit, which provides coverage for medications through commercial insurance plans.
Conversely, non-Medicare patients may or may not have a prescription drug benefit
(Printz, 2014). Even if medications are covered under a plan, Medicare Part D or
otherwise, prescription coverage varies widely (Hoadley et al., 2015b). For example, in
2018, once a Medicare patient enrolled in Part D hits the plan’s initial deductible and
coverage limits, they become responsible for paying drug costs until they meet the annual
out-of-pocket threshold. This period when costs are the responsibility of the patient is
called the coverage gap, also referred to as the “donut hole”. For example, in the case of
specialty drugs, costs quickly escalate and land a patient in the donut hole. Only after
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their OOP expenditures then reach the upper threshold established for the donut hole will
the insurer resume payment for a percentage of those costs (Medicare, 2018).
In 2018, the donut hole threshold was $3820. Due to changes in Medicare
coverage due to the Bipartisan Budget Act of 2018, provisions related to the donut hole
will change. Among factors that affect the cost of drugs to the Medicare Part D
beneficiary include the beneficiary’s income, whether the medication is brand or generic
and some additional cost breaks to the beneficiary by the drug manufacturer.
With the donut hole calculation ending for Part D beneficiaries, the change in how
medications are charged to the patient is expected to benefit patients required to pay the
bulk of their prescription costs until they reach the limit of costs established in the hole
(Medicare, 2018). With the elimination of the donut hole, it is not yet clear how
Medicare Part D will cover specialty medications, including oral cancer therapies
(Cubanski, Rae & Panchal, 2018). It seems likely that patients, Medicare and nonMedicare, will continue to bear increasing responsibility for the costs of oral cancer
therapy due to their insurer’s prescription drug benefit limits (Printz, 2014).
Cancer Treatment and Distress
Among the many stresses associated with a cancer diagnosis are pain, suffering
and the fear of death. For patients who have gone through treatment and are considered
survivors, they also experience distress that includes fear of recurrence, physical
challenges from rehabilitation after treatment (i.e., a new normal), financial concerns
related to continued clinical follow-up and the prospect of more treatment (Massa et al.,
2018; Nipp, Sonet & Guy, 2018). Studies confirm that cancer patients in treatment--or
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after treatment--report decreased quality of life (QOL) due to factors associated with FT
(Kale & Carroll, 2016; Delgado-Guay et al., 2015). These patients or cancer survivors are
at risk or suffer from depression and various anxiety disorders (Kale & Carroll, 2016). To
establish clarity about the impact that FT has on patients, Gordon and associates
conducted a systematic review of FT and cancer patients, covering 25 studies published
from 2013-2016. From this review, the most common factors associated with FT
included being female, having a low income, being treated with additional therapies after
standard treatments and a recent diagnosis (Gordon et al., 2017).

Cancer Care, Financial Toxicity and Distress
Since patients treated for cancer have been shown to be at higher risk for FT than
non-cancer patients, FT is of particular clinical concern in cancer care (Soni, 2015). In
addition to the cost of cancer therapies, the cost of supportive therapies, which reduce
neutropenic, nausea and vomiting, and anemia can also be high and have increased (Ell et
al., 2008).
A cancer patient’s distress, responding to the cost of cancer diagnosis and
treatment, can be amplified by the additional burden of FT (Kale & Carroll, 2016). For
patients in distress from FT, this distress can appear as worry, anxiety and/or depression
(Massa et al., 2018; Chino et al., 2017). Already challenged by the complexities of
getting through treatment, the stress of paying medical bills is common among these
patients, with studies estimating that 20-64% of cancer survivors reporting financial
stress and burden (Guy et al., 2014, Guy et al., 2013: Bernard, Farr & Fang, 2011).
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A cross-sectional study of 120 insured patients with cancer explored the
relationship between financial distress, emotional symptoms and overall distress. The
data, gathered from the InCharge Financial Distress/Financial Well-being Scale and the
National Comprehensive Cancer Network’s Distress Thermometer, showed that 65% of
respondents had clinically significant overall distress scores accompanied by at least one
emotional symptom (i.e., worry, depression, anxiety). The study also reported that due to
financial concerns, 40% of the sample needed to continue working to pay for treatment
and medical bills (Meeker et al., 2016).
Davidoff and colleagues surveyed 1868 Medicare beneficiaries from 1997-2007
(n = 10,047).

These patients spent a greater proportion of their incomes, often fixed, on

medical costs compared to those not diagnosed with cancer. Beneficiaries with cancer
had statistically significant mean higher OOP costs ($4,727) compared to those without
cancer ($3,209) (p <.001) (Davidoff et al., 2013).
In a 2015 review of literature about financial hardship and cancer treatment
focusing on 13 studies published between 2011-2014, McNulty and Khera determined
that patients are carrying more of the costs of cancer treatment. Based on their review of
studies, they identified risk factors associated with FT as patient and family
sociodemographics, employment and cancer diagnosis-related factors. Consequences of
FT included patient and family disability status, loss of income, lifestyle changes due to
reduced income and effect on cancer treatment—including nonadherence or
discontinuing cancer treatment (McNulty & Khera, 2015).
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Cancer Patients and Financial Toxicity
Current evidence examining the effect of FT on cancer patients is limited in scope
and consistency. Researchers use various methods and measurements and instruments,
including some unvalidated surveys and questionnaires. Examples include the HealthRelated Quality of Life (HRQOL), the Edmonton Symptom Assessment System (ESAS),
the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of
Cancer Therapy-General (FACT-G), the Comprehensive Score for Financial Toxicity
(COST instrument), health plan claims, medical record reviews, SEER Medicare data and
Medical Expenditure Panel Survey Data. These studies include a wide variety of
variables, disparate sample populations (advanced cancer patients, cancer survivors,
specific cancer diagnoses, older cancer patients) and frequently targeted sites limited to
just one health care system (Wheeler, Spencer & Pinheiro, 2018; deSouza et al., 2017,
Winn, Keating & Duestzina, 2016; Delgado-Guay et al., 2015; Huntington et al., 2015).
As a result, comparisons across studies are challenging. Therefore, as Meisenberg stated
in his 2015 commentary, it is difficult to establish the impact of financial hardship for
those patients undergoing treatment as well as those who have completed treatment
(Meisenberg, 2015). Two studies stand out as examples, however.
First, Yabroff and colleagues analyzed the experience of 1,202 cancer survivors
with financial hardship, based on survey results from the 2011 Medical Expenditure
Panel Survey (MEPS) Experiences with Cancer questionnaire. Respondents reported
financial hardship due to their cancer diagnosis if they had filed for bankruptcy, had
problems paying their medical bills, had borrowed money or had to adjust their finances
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due to cancer treatment. The analysis showed that younger cancer patient survivors (1864 years old) experienced more financial hardship (28.4%) than older cancer survivors (>
65 years; 13.8%). Those younger survivors, who were uninsured and had lower family
income, experienced more psychological financial hardship (Yabroff et al., 2016).
Ekwueme and colleagues studied costs of cancer for survivors. For the period
2008–2011, male cancer survivors had mean annual health care expenditures of $8,091,
compared with $3,904 among males with no cancer history. Study results for female
survivors had mean annual medical expenditures of $8,412, compared with $5,119
among women without a cancer history. (Ekwueme et al., 2014).
Out-of-Pocket (OOP) Expenses
OOP expenses are considered any expense or bill that is the responsibility of the
patient and not covered by health insurance or outside sources of health expense
coverage. These OOP expenses can be deductibles and copayments that insurance does
not cover. They also can be the expense of access to ongoing medical care, which can
include transportation, hotel, food, medications not covered by insurance (Cabrerra et al.,
2018; Altice et al., 2017; Chino et al., 2017).
Cancer survivors have reported higher OOP spending on healthcare than noncancer survivors. In a review of medical and productivity costs of cancer survivors from
2008-2011, Ekwueme and colleagues estimate that ongoing medical bills for those
diagnosed with cancer are 160-260% higher than noncancer patients (Ekwueme et al.,
2014).
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McNulty and Khera’s 2015 MEDLINE literature review of articles published
1986-2014 about financial hardship and cancer treatment compiled risk factors and
consequences of FT to patients and families. Among the risk factors were patient and
family socio-economic status, employment, logistics to get to and receive treatment and
the stage and trajectory of disease. Consequences from FT included decreased
adherence to treatment, lifestyle changes (avoiding purchases, reduced spending on food
and staples in the household), borrowing money and bankruptcy (McNulty and Khera,
2015).
A 2017 study of 400 breast, colo-rectal, lung and prostate patients in rural
Australia documented that 21 weeks after their cancer diagnosis, 11% had spent more
than 10% of their household income on treatment-related costs. For this sample of
patients, OOP costs were on average $2,179AU (2018 AUD dollars were 1.39 > US
dollars) (Newton et al., 2018). Rotenstein and colleagues conducted a retrospective
analysis of commercial insurer prescription drug claims for seven years for 13 FDA
approved oral oncolytics. The range of monthly OOP costs representing monthly
prescriptions for 44,113 patients was found to be a range of no cost to as high as $14,157
with a mean monthly per prescription cost of $82.82. The mean monthly OOP was
$2,901 (Rotenstein et al., 2018). Based on data from a 2008–2012 MEPS, Guy and
colleagues compared 4,271 adult cancer survivors with 96,780 individuals without a
history of cancer to determine their OOP cost burden. The analysis showed that cancer
survivors were more likely to report high OOP expenses, especially when they were poor
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(18.4%). In addition, cancer patients were more likely to delay medical care (21.6%) or
delay medical care (19.2%) (Guy et al., 2014).
Out-of-Pocket Costs as Source of Distress
A 2018 qualitative study by Ferrell and associates confirmed that from the patient
and family member perspective, financial distress can be more distressing even than the
physical, emotional and spiritual distress from cancer and its treatment. The study results
were based on a convenience sample of 20 family caregivers of cancer patients with solid
tumors, who were interviewed one time for 20-40 minutes each as part of a larger
randomized trial about support interventions. The caregivers described their own
physical, psychological, social and spiritual wellbeing and financial strain related to the
patient’s cancer diagnosis and treatment. The researchers reported that caregivers had
extensive financial concerns; most said they were struggling to pay for care as OOP
expenses, pay household bills and maintain their credit. They stated among the costs
associated with medical care were last minute airplane flights, gasoline, overnight hotel
stays, restaurant meals and vehicle maintenance. For caregivers with self-reported
financial stability with adequate healthcare coverage, they also stated they were anxious
about their ability to cover future health care expenses (Ferrell et al., 2018).
Financial Hardship
In an analysis of 19.6 million cancer survivors from 2011 MEPS data, 28.7%
reported financial burden due to cancer diagnosis and treatment. Respondents reported
that 7.6% had borrowed to pay their bills or incurred debt, with 4.2% borrowing less than
$10,000 and 3% borrowing more than $10,000. Of the respondents, 1.4% had declared
bankruptcy. Approximately 21% of these cancer survivors were worried about their
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medical bills, especially as they mushroomed, with 11.5% stating they could not cover
their medical bills. Based on accompanying physical and mental component scores, those
with financial challenges had increased depression and worried more about recurrence
(Kale & Carroll, 2016).
Using a 2012 LIVESTRONG database of 4,719 cancer survivors, Banegas and
colleagues determined that approximately one-third of cancer survivors had gone into
debt, and 3% had filed for bankruptcy. Of those going into debt, 55% of respondents
had a debt of $10,000 or more (Banegas et al., 2016).
Zheng and associates analyzed MEPS data from 2008-2012 to determine the
economic burden experience by cancer survivors: breast (n = 1568); prostate (n =1170)
and colorectal (n =540). That burden experience included high medical bills and lost
productivity (missed work; days in bed). Their analysis indicated that cancer patients
experience a statistically higher economic burden compared with those without a cancer
history (Zheng et al., 2016).
From a pilot study Zafar and colleagues reported about OOP costs and the FT
experience of 246 cancer patients with solid tumors. They reported that 42% of patients
receiving chemotherapy or hormonal therapy reported significant financial burden
associated with their OOP expenses. For those who did not receive financial assistance
with the OOP costs of their treatment, their median monthly OOP cost for cancer
treatment was $708. Not surprisingly, results indicated that FT increased when patients
were non-white, lower income and had higher psychosocial distress (Zafar et al., 2013).
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In a study of 2,494 women surveyed from the Carolina Breast Cancer Study
through the North Carolina Cancer Registry (2008-2013), Black women treated for breast
cancer experienced worse financial impact when compared to white breast cancer
patients. Based on the study’s multivariable logistic regression analysis, black women
experienced significantly worse financial impact during their cancer treatment.
Additional factors affecting the experience of FT included loss of job and income and
challenges with transportation (Wheeler et al., 2018).
Financial Toxicity and Quality of Life
Studies have explored relationships among the experience of FT, patient’s
decreased QOL and patient mortality. Zafar and colleagues have proposed factors that
may be associated with cancer patients experiencing a perception of high FT that affects
mortality (Zafar, 2016). These factors include decreased QOL, poorly-perceived
wellbeing (defined as an “undesirable lifestyle”) and less care due to OOP costs (less care
associated with non-adherence to prescribed treatments) (Zafar, 2016). Additional studies
have looked at copay thresholds, when cancer patients may decide not to take prescribed
medications given orally because they cannot afford the OOP cost of treatment
(Dusetzina et al., 2013).
In a cross-sectional study by Delgado-Guay and associates, which evaluated
overall suffering and QOL in 144 advanced cancer patients treated at a comprehensive
cancer center and a public hospital in Texas, more than 30% of patients reported that
financial distress was more than physical distress or distress from family relationships or
emotional distress. Study data was compiled from validated depression, functional
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assessment QOL and social support instruments. Moreover, study results reported that
patients treated at the public hospital had twice the financial distress compared to those
treated at the cancer center.
According to this study’s results, distress manifested as depression, anxiety and
that the patient’s perception of QOL had deteriorated. The authors went on to report that
for patients with advanced cancer, financial distress is rarely evaluated or reported.
Delgado-Guay and associates suggest that the impact of financial distress is not yet
quantified related to other distress-related factors during diagnosis and treatment
(Delgado-Guay et al., 2015).
In a 2014 observational, cross-sectional study by Chino and associates of 174
advanced cancer patient perception of financial burden, 47% reported significant or
catastrophic financial burden. The study results suggest that addressing the financial
burden with cancer patients can affect their general satisfaction with the quality of their
cancer care and may positively affect adherence to treatment and patient QOL outcomes
(Chino et al., 2014).
Financial Toxicity Non-Adherence to Treatment
A few studies have established a relationship between health care decisionmaking tempered by financial distress. These decisions have resulted in patients taking
less than their prescribed medications, less monitoring of treatment side effects, less
attention to signs of recurrence, lifestyle changes that avoid regular primary care visits,
eating less healthy diets and exercising less regularly. These behavior-based decisions
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impact whether cancer patients can do well when treated for their malignancies (Wheeler
et al., 2018; de Souza et al., 2017; Bestvina et al., 2014).
Desetzina and colleagues reported in a 2014 analysis about patient adherence to
imatinib, a tyrosine kinase inhibitor, used as a treatment for patients with CML. They
reported 2002 thru 2011 data from large employers, health plans and government insurers
for 1,541 patients with initial insurance coverage for the treatment. The monthly
copayment for the medication averaged $108 with a range of copayments $0 to $4,792.
The study data suggests that when OOP costs of the treatment were higher, patients had
lower adherence to the treatment, estimating 42% of patients were more likely to be
nonadherent to the treatment with higher copays. Therefore, patients with higher
copayments were more likely to be nonadherent or discontinue treatment. Moreover,
70% of the respondents were most likely to stop taking the therapy within six months of
starting therapy when the monthly co-pay was more than $53 (Desetzina et al., 2014).
From a cross-sectional survey of 164 patients participating in a copay assistance
program and treated for solid tumor malignancies 2019-2011, Zullig and colleagues
reported that 45% of the patients reported not adhering to prescribed prescriptions due to
the cost of treatment. This non-adherence included not filling their prescriptions, taking
less than the prescribed treatment or taking medication that was prescribed for others.
The results also indicated that those who were non-adherent to the prescribed treatment
spent less of their household income on food and clothing and were more likely to use
credit cards to pay for medication (Zullig, Peppercorn & Schrag, 2016).
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Winn and associates evaluated the affordability of anti-cancer therapies (tyrosine
kinase inhibitor) given orally for CML. Using the SEER-Medicare database from 20072011 of 393 patients, only 68% started therapy within three months of diagnosis. The
researchers suggested that the OOP costs may prevent patients from starting therapy as
prescribed. From the study, factors contributing to nonadherence to treatment decreased
with age, especially for patient 80 years or older (Winn et al., 2016).
Finally, in a 2014 cross-sectional survey study at Duke Cancer Institute, 300
patients during 2012-2013 were asked if they had discussed with their oncologists the
OOP costs for their cancer treatment given orally. Only 19% of them reported they had
discussed costs with their oncologist. As to OOP cost of the therapy affecting whether
they followed the medication instructions as prescribed, 27% stated they did not follow
through taking the medication as prescribed, 14% stated they missed medication doses
and 11% stated they took less than the medication prescribed—all due to the cost of the
medication (Bestvina et al., 2014).
Gap Analysis
This study attempts to fill a gap in what is known about the experience of FT for
patients treated for cancer with therapies given orally and the relationship of that
experience with the patient’s perception of distress and adherence to the prescribed
treatment. Few studies have focused on FT experienced by cancer patients. In September
2017, a search of the PubMed database of studies from the past ten years resulted in few
studies about FT and cancer (44), financial hardship and cancer (61) and financial distress
and cancer (44). This accounting of studies compared with a PubMed search not linked to
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the word “cancer” of FT (55), financial hardship (433) and financial distress (152)
(Carrera et al., 2018).
A 2016 systematic review of the previous six years of peer-reviewed studies
looked at the cost of illness and its effect on cancer patients. The review confirms that
FT studies lack consistency of rigor in their design and methods (Gordon et al., 2017).
Gordon’s review identified 25 relevant studies, with only 15 from the United States.
Eighteen studies were cross-sectional; the remainder of studies were prospective or
retrospective cohort studies. The study measures varied with some reporting FT as a
subjective measure, with 15-73% of respondents reported experiencing FT. Objective
measures of FT included non-adherence to treatment, delays in starting treatment, not
proceeding with treatment and changes in insurance coverage affecting the patient’s
experience of FT. This systematic review confirms there are precious few rigorous
studies about FT with cancer patients and any comparison of data or conclusion across
studies is problematic (Gordon et al., 2017).
To date, studies of FT in cancer patient populations have adopted various study
designs, procedural methods and data analysis. In general, studies have had small sample
sizes or have performed secondary data analysis, extracting data about patients’ financial
toxicity experience based on broad interpretations (Gupta et al., 2018; Huntington et al.,
2015; Pelletier & Bona, 2015; Delgado-Guay et al., 2015).
The literature review for this study confirms that measuring FT in cancer patients
is a new focus of clinical care. Only one measurement instrument, the Comprehensive
Score for Financial Toxicity (COST), has a published evaluation of its reliability and
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validity (deSouza et al., 2014). Otherwise, the assessment of FT in cancer patients is
based on a broad list of instruments. Without a focus on FT, many instruments are not
established as reliable, without published psychometric evaluations related to FT and
specific populations (Gupta et al., 2018; Pelletier & Bona, 2015; Delgado-Guay et al.,
2015; Chino et al., 2014; Bestvina et al., 2014). In some studies, there has been a focus
on evaluating clinical depression or anxiety as equivalent to the experience of FT and
distress (Kale & Carroll, 2016; Meeker et al., 2016). Data has also been gathered from
surveys, the medical record or large insurance claim or cancer-registry data bases
(Yabroff et al., 2016; Chino et al., 2014; Guy et al., 2014; Guy et al., 2013; Wheeler et
al., 2013).
Several thought leaders in the emerging field of FT have weighed in with
insightful commentaries about the need to further study FT and its relationship with the
patient’s psychosocial status and adherence to treatment (Meisenberg, 2015; Zafar, 2015;
Kantarjain et al., 2014; Light & Kantarjian, 2013; Ubel, Aberneth & Zafar, 2013). But
those commentaries refer to few published studies based on clinical data, with their
commentaries urging the need for further research. They state that a foundation to build
effective interventions to address FT requires clinical attention and study. Data-based
studies form the foundation for clinical care, which can lead to more open discussions
between patients and their providers about the value of treatments within a care plan.
Studies also can serve as a foundation for more effective decision-making and guidelines
for standards of care (Santacroce, Tan & Killea, 2016; Delgado-Guay et al., 2015).
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Moreover to date, FT studies do not focus on cancer patient populations with any
specificity or acknowledgment of complexity. These studies are limited in their insights
about cancer patients with a particular diagnosis, stage of their cancer, choice of novel
treatments, time or duration of their treatment or survivorship status (Wheeler, et al.,
2018; McNulty & Khera, 2015). Analysis of health care expenditures associated with
insurance carriers provide some understanding of the financial burden of care. But little is
known about FT when insurance coverage changes, when those changes affect the
patient’s OOP costs and financial burden (Gupta et al., 2018; Fessele, 2017; Fenn et al.,
2014).
Summary of Literature
This review of the literature related to FT in cancer patients confirms a challenge
to patients undergoing treatment that is becoming more concerning. Moreover, the high
costs of cancer therapies given orally have become more the responsibility of the patient
(KFF, 2018; Guy et al., 2015; Hoadley, 2015a). These OOP costs are the source of
distress to patients, as evident by patients’ reports of more worry, depression and anxiety
(Massa et al., 2018; Chino et al., 2017; Delgado-Guay et al., 2015).
Studies about FT associated with cancer treatment have focused on financial
burden of treatment (Guy et al., 2013; Guy et al., 2014; Bernard et al., 2011). To define
the components and impact of FT, studies have used a variety of study designs,
measurement strategies and instruments (Gupta et al., 2018; Huntington et al., 2015).
Some FT measurement instruments have been evaluated for reliability and validity of
findings (deSouza et al., 2017). The majority of studies have not used reliable
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measurement instruments that can produce reliable, valid data (Gupta et al., 2018,
Pelletier & Bona, 2015; Delgado-Guay et al., 2015. Chino et al., 2014; Bestvina et al.,
2014).).
The first documented reliable FT instrument to produce valid data is the COST.
Since it is the first FT instrument tested as reliable, use of the COST instrument is a
method to establish standard FT measurement across different studies (deSouza et al.,
2017).
Gaps in what is known about the relationship of FT to the experience of patients
treated for cancer include the nuances of financial distress and adherence to treatment,
decision-making and patient preferences about their plan of care (Santacroce et al., 2016;
Delgado-Guay et al., 2015). Those who have studied FT recommend establishing
coherence in the approach to FT, understanding the context in which FT occurs and
conducting more studies with robust designs using reliable measurements and
instruments (Carrerra et al., 2018; Altice et al., 2017). Yet no studies to date have
studied cancer patients receiving therapies given orally and the relationships to their
adherence to prescribed treatment, their experience with FT and their perception of
distress.
To better inform health care professional discussions with patients about
treatment and their impact on patients and their family members, this study intends to
better describe the participant experience of FT and its relationship with patient distress
and non-adherence to treatments given orally.
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CHAPTER III
METHODS
This chapter includes a discussion of the study design; a description of the
population, study procedures for participant recruitment and data collection, and the plan
for data management and statistical analysis.
Purpose and Specific Aims
The purpose of this study was to describe the relationships between the patient
experience of financial toxicity (FT), patient perception about distress and patient
adherence to prescribed therapy in a sample of cancer patients treated with therapy given
orally.
Study Design
This study used a descriptive cross-sectional correlational design to describe the
relationships between the patient experience of FT, patient perception about distress and
patient adherence to prescribed treatment in a sample of cancer patients treated with
therapy given orally.
Sample
The sample of participants had received or are receiving treatment for
hematologic and solid tumor malignancies given orally.
The inclusion criteria for participants were adult patients (21 years or older) who
are Spanish or English speaking, have the ability to read English and have an initial
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diagnosis of these malignancies: Breast cancer, head and neck cancer, Hodgkin’s
Lymphoma, lung cancer, leukemia, lymphoma, melanoma, multiple myeloma,
myeloproliferative neoplasms, pancreatic cancer and prostate cancer. Participants’
oncologists had prescribed a cancer treatment regimen for at least four weeks and given
orally. The participants’ health insurance coverage included private health insurance or
coverage by Medicare (Medicare Fee for Service (FFS), Medigap or Medicare Part C
(Advantage).
The exclusion criteria for study participants included patients who had not been
prescribed cancer treatment given orally (i.e. infusion only, radiation and/or surgery only)
and those receiving in-patient cancer treatment. In addition, excluded study participants
were those covered by Medicaid or those without health insurance coverage.
Setting
The patient education/advocacy organization Patient Power® was the setting for
the study. Patient Power® provides education, information, resources and support to
patients diagnosed with cancer, their family members and caregivers.
Patient Power® is a service of Patient Power®, LLC, based in Carlsbad, CA with
members participating from around the world (Patient Power, 2018). In 2005, two
health communications pioneers, Andrew and Esther Schorr, founded Patient Power®.
The Schorrs have extensive professional and career experience in healthcare
communications. Moreover, their commitment to Patient Power® is based on their own
experience with cancer: Andrew is a two-time cancer survivor (chronic lymphocytic
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leukemia (CLL); myelofibrosis (MF). He was first diagnosed in 1996. Esther has been
his care partner over 20+ years.
The foundation for Patient Power®’s communication and exchange is its openaccess web site: www.patientpower.info. As of September 2018, Patient Power had
approximately 23,000 contactable community members. For a participant to become a
contactable community member (registered, receiving a free subscription to Patient
Power’s information and resources), the participant is required to register (establish a
password and submit the participant’s e-mail address to Patient Power®). With
membership, the participant receives e-Alerts and invitations to online and in-person
events.) Tables 3-1 shows the demographics of the Patient Power® membership. Table
3-2 provides a breakdown of its membership.
In 2018, the Patient Power® site had approximately 70,000 visits to the site per
month. Patient Power® also builds traffic to its site from its Facebook community page
(35,000 visits/week) and from additional website platforms: LinkedIn, Twitter, and other
social media channels.
Patient Power® follows HIPAA privacy guidelines to protect membership data.
It complies with the HONcode Standard for trustworthy health information. It is in
partnership with major medical institutions and advocacy groups to continually ensure
the veracity of its information and resources. Among its collaborative partners for
education and advocacy are the Leukemia and Lymphoma Society, CLL Research
Foundation, Myeloma Crowd, MD Anderson Cancer Center and City of Hope National
Medical Center.
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Figure 3-1
Patient Power® Community Demographics (2016)
(Used with Permission, Patient Power®)
___________________________________________________________________

Figure 3-2
Patient Power® Member/Subscriptions (2018)
(Used with Permission, Patient Power®)
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Sample Size
This study’s target sample size was based on an a priori analysis from three
previous studies about FT as a clinical factor in patient care (Gupta et al., 2018;
Shankaran et al., 2018; Huntington et al., 2015). Samples from those studies included
sample sizes of 118, 34 and 100 patients. In addition to supporting a target sample size, a
power analysis was calculated using G*Power version 3.1.9.2. The G*Power calculation
used a medium effect size of 0.15, based on a one-way independent analysis of variance
(ANOVA) at 0.95 power, eight anticipated predictors and significance of 0.05. The
G*Power calculation resulted in 89 participants. Therefore, taking into account previous
study samples, the G*Power calculation and anticipated incomplete, missed and outlier
data, this study’s sample size was targeted at a minimum of 120 participants for
responses to contribute to the data analysis.
Protection of Human Subjects
The study was reviewed by the Institutional Review Board of the University of
San Diego. (Appendix A.) This review confirmed that study participants were recruited
according to the National Institute of Health (NIH) guidelines Protecting Human
Research Subjects (NIH, 2018). The study design did not present inherent adverse
physical effects or undue burden for the participants.

42
Study Procedures
Recruitment of Participants
The study investigator recruited a convenience sample of participants by
accessing participants (patients only) from the Patient Power® community. With
permission from the Patient Power® site administrator, the study investigator posted
information about the study (including the inclusion/exclusion criteria) on the Patient
Power® website. (Study Blurb: Appendix B.) If potential participants were interested in
reviewing more information about the study or proceeding to sign up as a study
participant, the study instructions guided interested members from the Patient Power®
community to proceed via link to Website #1, managed by the investigator, with more
information about the study and procedures provided about joining the study (Appendix
C, Web site #1 content.).
On Website # 1, the Study Investigator provided potential interested participants
with a study synopsis, FAQs about the study and the Study Investigator’s contact
information if potential participants had questions or need further clarification about the
study. Website #1 also included instructions to sign up for the study, which included
instructions to complete the informed consent and the informed consent itself.
If after reviewing the study information on WebSite #1, the participant did not
want to participate in the study, there was no further contact with the Patient Power®
member.
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Data Collection
When a participant responded that he/she wanted to sign up for the study (signed
informed consent posted), the Study Investigator contacted the participant via e-mail with
instructions to proceed to a participant password-protected site to complete the three
study instruments (Appendix D. Web site #2). Web site #2 (Advantage Survey Monkey
platform) included the study synopsis (again), contact information about the Study
Investigator and instructions to proceed to complete surveys listed in Appendix E, F and
G. Participant’s responses were automatically entered into a .cvs file within Advantage
Survey Monkey® and only accessible to the investigator.
At all times, participation in the study remained voluntary. Participants could
choose to answer only those questions they chose to answer.
Data Management
To secure the data and ensure confidentiality, participants and their survey
responses were deidentified. The study investigator accessed participant data and survey
results from a password protected file, provided by the Advantage Survey Monkey®
platform (https://www.surveymonkey.com). The .cvs file was uploaded to the
investigator’s computer. Files of the dataset were stored in a secured environment
(lockable computer system with passwords).
To prepare the data for analysis, the Study Investigator reviewed and cleaned the
data, accounting for missing, invalid or outlier data. The data was coded to assess for
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internal validity. Data was then transferred to the SPSS v26 Statistical Package for data
analysis.

Study Measurements
Operational Definitions of Terms
As a review, here are operational definitions pertinent to this study:
Financial Toxicity (FT): In cancer care, the objective and subjective financial
consequences of cancer treatment, which may include significant OOP costs, loss of
income, and caregiver burden. Since 2011, the term financial toxicity also has been
associated with patients diagnosed with cancer who face significant financial challenges
related to precision medicine as a foundation for treatment (Carrera, 2017; Zhang,
Hueser, & Hernandez, 2017).
Cancer Treatments given Orally: Molecular and genetically-based cancer treatments that
are prescribed in oral form (i.e. not intravenous or intraperitoneal infusions) (Carrera,
2017; Zhang et al., 2017).
Perception of Distress: Perception of Distress is an unpleasant emotional state
experienced by an individual, which may affect feelings, thoughts, and actions. It can
include feelings of unease, sadness, worry, anger, helplessness, and guilt (NCCN, 2018).
Adherence to Treatment: Taking a prescribed medication or treatment exactly as
prescribed, including dose or rate, schedule and formulation (Bestvina et al., 2014; Zullig
et al., 2013).
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Instruments
Demographic Questionnaire. The first instrument was the Demographics
screen. It included standard demographic questions, including cancer diagnosis, gender,
age, gross household income, level of education, employment status and insurance
coverage, as well as questions about the participant’s cancer therapy given orally.
(Appendix E).
The study used two validated study instruments:
Comprehensive Score for Financial Toxicity (COST). The COST is a
measurement instrument to assess a respondent’s experience with FT (Appendix F.). It is
an 11-item instrument that covers one financial question, two resource item questions and
eight affect-focused questions about the respondent’s experience with FT. Lower COST
scores indicate higher levels of FT (DeSousa et al., 2017; DeSouza et al., 2014).
The COST measure demonstrates high internal consistency and test-retest
reliability. Specifically, COST scores have been shown to correlate with income
(correlation coefficient r = 0.28; p<.001), psychosocial distress (r = 0.26; p<.001), and in
comparison to the Health-Related Quality of Life (HRQOL) instrument, as measured by
the FACT-G (r = 0.42; p<.001) and by the EORTC QOL instruments (r = 0.33; p<.001)
(DeSousa et al., 2017; DeSouza et al., 2014). The COST instrument has a Cronbach
alpha value of > .90., confirming reliability and that it generates valid data (DeSousa et
al., 2017; DeSouza et al., 2014).
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The COST instrument is relatively new to research practice with a few studies
reporting results when used (Huntington et al., 2015). In a 2013 study by Zafar and
associates in two Chicago-area hospitals, the COST measure demonstrated high internal
consistency and test-retest reliability when evaluating FT (Zafar to al., 2013c). Although
considered a reliable instrument to evaluate FT in cancer patients, the COST is not yet
widely used (Huntington et al., 2015).
National Comprehensive Cancer Network (NCCN) Distress Thermometer
(DT). The National Comprehensive Cancer Network (NCCN) Distress Thermometer and
accompanying Problem List (DT) (Appendix G) has been widely used internationally
and in a variety of clinical cancer patient care settings (NCCN, 2018; Baken & Wooley,
2011). The DT consists of a 1-10 scale (0 = no distress; 10 = extreme distress),
identifying any source of distress to the patient. Scores of 4 or higher on the DT suggest
clinically significant distress (Ploos van Amstel et al., 2017).
The DT has been shown to effectively assess distress in cancer patients (Mitchell,
2007; Donovan et al., 2014). Its reliability and validity as a measurement instrument has
been demonstrated in 38 pooled studies, representing 14,000 patients with cancer. The
pooled sensitivity of the DT has been established at 81% (95% CI, 0.79-0.82) at a cutoff
score of 4 (Ma et al., 2014). The DT has a specificity of α = 0.70 for detecting clinical
levels of distress (Jacobsen et al., 2005).
When a patient’s score is 4 or greater, the provider can further target the patient’s
distress by assessing the patient’s response to the instrument’s 39-item accompanying
Problem List. From the Problem List, items are categorized in 5 areas: practical, family,
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emotional, spiritual/religious and physical (NCCN, 2018). Under the Practical Problems
category, Insurance/Financial is an option that the patient can choose to mark: yes or no.
When the patient marks yes, the provider can follow-up on that problem area with
education, support and resources (NCCN, 2018). Two studies have validated the DT
instrument with the expanded Problem List, which includes Insurance/Financial as a
Problem (positive predictive value: 39%: negative predictive value: 95%.) (Graves et al.,
2007; Tuinman et al., 2008).
Data Analysis
All data analysis was performed using IBM SPSS Statistics, version 26.
The study’s three aims and the statistical analysis plan for each aim follows:
Aim #1. To describe sociodemographic, clinical and financial characteristics, the
experience of FT, perception of the level of distress, and adherence to treatment in a
sample of adult participants who have received or are receiving treatment given orally for
hematologic or solid tumor malignancies.
To meet this aim, descriptive statistics were computed for all study variables to
determine the overall characteristics of the sample and the distribution of variables.
Aim #2. To describe relationships between participant sociodemographic, clinical and
financial characteristics, participants’ experience of FT, participants’ perception of
distress, and participants’ adherence to treatment.
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To meet this aim, the study analysis examined relationships between the
covariates of participant sociodemographic, clinical and financial characteristics,
participants’ experience of FT, participants’ perception of distress, and participants’
adherence to treatment. Variables underwent bivariate analysis and modeling. Analysis
was expected to control for the demographic characteristic. Variables were entered in the
logistic regression model and examined for linearity, multicollinearity and outliers.
To establish potential associations between the study’s variables (categorical),
Pearson’s Coefficient Correlation analysis was performed. Then nonparametric analysis
(Spearman’s Rank Order Correlation) was performed on selected variables to determine
if any study variables had significant correlation not established with parametric analysis.
Aim #3. To explore the likelihood that participant experience of FT predicts participant
perception of distress and non-adherence to the treatment given orally.
From the bivariate analysis completed for Aim #2, variables significant at p < 0.5
were to be entered in logistic regression models to determine the likelihood that
participant experience of FT predicts participant perception of distress and/or nonadherence to the treatment given orally.
Strengths and Limitations of Methods
By using an on-line patient education/advocacy site to recruit study participants,
the participants were self-selected as a) cancer patients, b) cancer patients treated with
cancer treatments given orally, and c) cancer patients who were motivated to know and
learn about their cancer, its treatment and the operational issues related to their treatment.
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Participants recruited from the advocacy site, Patient Power®, were not
representative of cancer patients, any standardization of insurance coverage for patients
or were receiving treatments prescribed for all cancer patients.
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CHAPTER IV
RESULTS
This chapter presents the results of the study, including a narrative description,
supported by 25 tables supporting the data analysis. (Tables follow this chapter.) The
analysis described the data, using descriptive statistics. Further analysis addressed each
of the study’s aims, establishing relationships among the study variables and whether the
total COST instrument data (representing financial toxicity (FT) could predict patient
distress or adherence to treatment.
The Study
This study employed a descriptive, cross-sectional design using convenience
sampling and validated survey instruments. The study described characteristics about the
sample, relationships among the sample’s variables related to the experience of FT,
perception of distress and adherence to prescribed cancer treatment given orally.
Data Collection
The study’s data were collected on-line from 136 participants, who were members
of the patient education/advocacy community, Patient Power®. Participants in the study
were self-identified as diagnosed with a malignancy and prescribed a cancer treatment
given orally. Participants completed three study instruments—the 27-question
Demographic Questionnaire, the 11-item, Likert-scale Comprehensive Score for
Financial Toxicity (COST) and the 0-10 scaled National Comprehensive Cancer Network
(NCCN) Distress Thermometer (DT).
April 15, 2019.

The study period was six weeks, March 1 to
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The study investigator accessed the participant data and survey results from a
password protected file, provided by the Advantage Survey Monkey® platform. All data
files were uploaded to the investigator’s computer and stored in a secured environment
(lockable computer system with passwords).
To prepare the data for analysis, the Study Investigator reviewed and cleaned the
data, accounting for missing, invalid or outlier data from all three study instruments.
Pairwise deletion was the method used to account for any missing data during data
analysis. Continuous data were evaluated through parametric testing; linearity was
established via scatter plot evaluation.
The data was transferred to SPSS v26 Statistical Package for data analysis.
Study Aim #1
Aim #1
Based on the sample data, to describe sociodemographic, clinical and financial
characteristics, the experience of FT, perception of the level of distress, and adherence to
treatment in a sample of adult participants who have received or are receiving treatment
given orally for hematologic or solid tumor malignancies.
Aim #1: Analysis
To address Aim #1, descriptive statistics, specifically frequencies and
percentages, were calculated to provide a summary of the characteristics of the sample
population and the measures captured in this study.
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Demographic Characteristics
The study sample included 136 participants, who completed or partially
completed the study’s three on-line surveys. Tables 1a, 1b, 1c compile demographic
characteristics about the study’s participants. Participants completed the three surveys at
one time. For some of the questions related to the COST instrument (FT) and the
Distress Thermometer (DT), participants were asked about their perceptions at two time
points: 1) Perceptions at one-week post start of treatment prescribed orally, and 2)
Perceptions at six months post start of treatment prescribed orally.
More women (n =75, 51.1%) than men (n = 61, 44.9%) participated in the study.
More than two thirds of the participants were > 65 years old (n = 93, 68.4%)—an age
threshold expected since the study focused on participants diagnosed with malignancies
more prevalent with age. In addition, many of the treatments for the cancer diagnoses
represented in the study sample are treatments given orally.
The majority of participants were married or had a domestic partner (n = 112,
82.4%). Participants’ educational backgrounds skewed to well-educated with almost one
third completing some college credits (n = 48, 35.3%). Approximately two thirds of study
participants had earned graduate credit and/or graduate degrees (n = 88, 64.7%).
Due to the age of the study participants, most participants at the time of the study
period were not employed (n = 93, 74.4%). However, 54% of the study participants
reported they were employed when they started their cancer treatment given orally (n =
67, 54%). Of the study participants, two thirds reported that their cancer treatment did not
affect their employment (n = 80, 65.6%).
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Clinical Characteristics
The most common diagnoses of the study participants were chronic lymphocytic
leukemia (CLL) (n = 54, 41.5%) and multiple myeloma (MM) (n = 34, 26.1%),
accounting for more than two thirds of the survey participants’ diagnoses. The
treatments that participants were prescribed in oral formulation were in keeping with the
recommended or standard-of-care treatments for their cancer diagnoses. The most
frequently cited therapies reported by the participants were imbrutinib (Imbruvica®),
lenalidomide (Revlimid®) and ruxolitinib (Jakafi®). Most of participants (n = 118,
86.7%) reported that despite challenges to stay on their treatments given orally, they
maintained their treatment dosing schedules.
Only 2.9% (n = 4) of study participants reported that they had skipped taking their
cancer treatments given orally due to the cost of treatment. Few study participants
reported that they had stopped taking their non-cancer medications (n = 5, 3.8%) or took
some of their non-cancer medications (n = 5, 4.0%) or adjusted the dose of their noncancer medication (n = 8, 6.5%) due to the cost of their cancer treatment (Table 4-1b).
Financial Characteristics
Almost three fourths of study participants responded that they financially
supported themselves and a partner (n = 92, 75.5%). Another quarter of the participants
responded that they were single, financially supporting only themselves (n = 28, 24.0%.)
Of those responding to the question about gross income, 70% of participants had a gross
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income <$100,000/year (n = 82, 70.0%) with the remaining participants reporting a gross
income of >$100,000/year (n = 35, 29.8%) (Table 4-1c).
Covering the Cost of Cancer Treatment Given Orally
The majority of the sample participants were covered by health insurance (n =
128, 98.4%), which fully or partially covered their cancer treatments given orally. Health
insurance coverage represented in the sample included Medicare alone (n = 32, 27%),
Medicare with Medigap coverage (n = 33, 27.5%), Medicare Advantage (a managed care
coverage option for Medicare) (n = 7, 6%), and private insurance (n = 46, 39.0%). Most
participants had prescription drug coverage, either Medicare Part D (n = 65, 56.0%) or
private insurance drug coverage (n = 47, 40.5%) (Table 4-1b)
For study participants receiving financial support from pharmaceutical,
foundation or other non-insurance sources to cover their treatment cancer costs, they
were generally split between those who received support (n = 57, 46.3%) and did not
receive support (68, 54.0%). Of note, approximately half of study participants did not
respond to the question about the percentage of financial support received from noninsurance sources. For study participants who did respond about receiving non-insurance
support for their treatment (n = 66, 52.8%), 27.2% (n = 34) received 50-100% support;
7.2% (n = 9) received 20-50% support and 10.4% (n = 13) received < 20% support
(Table 4-1b).
After cancer treatments given orally were covered by insurance or non-insurance
sources, 91% of study participants reported that they were responsible for < 20% of the
cost (n = 52, 43%); 20-50% of the cost (n = 22, 18%) and 5-100% (n = 6, 5%). The
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remaining participants (n =30, 16.5%) reported they were partially responsible for the
cost of their treatment, based on copays and various OOP cost calculations. (Table 4-1b)
Participant Experience of Financial Toxicity
The COST instrument scores, which indicated participants’ perception of their FT
experience at one week and six months after the start of treatment, were analyzed as
percentages, frequencies, means and standard deviations (SDs) (Tables 4-2a, 4-2b).
Comparing the total COST scores (n = 119) at the two time points, the means and
range of scores were similar: at seven days post start of treatment (M = 25.13, SD =
5.154, range: 10-39); at six months post start of treatment (M = 25.17, SD = 5.614; range
8-39). (NOTE: Overall range of COST scores: 0-44; COST score cutoff for high FT =
≤24; for low FT = > 24.)
For the eleven individual COST items scored on a 5-point Likert scale, Table 4-2a
and 4-2b provide frequencies and percentages of responses. For participant perceptions
at one week after cancer treatment began, COST items that prompted quite a bit or very
much concern were “feel no choice about cost of care” (n = 89, 75.4%), “worry about
future financial problems due to illness” (n = 70, 72.2%), “higher than anticipated out of
pocket medical expenses” (n = 74, 67.1%), “reduced satisfaction in current financial
situation due to cancer treatment” (n = 69, 58.5%), “ability to meet monthly expenses”
(n = 60, 52.1%) and “overall financial stress” (n = 53, 45.7% (Table 4-2a).
For participant perceptions at six months after beginning their cancer treatment
given orally, items that prompted quite a bit or very much concern were “feel no choice
about cost of care” (n = 92, 80.0%), “worry about future financial problems due to
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illness” (n = 80, 68.9%), “higher than anticipated out-of-pocket medical expenses” (n =
69, 59.4%), “reduced satisfaction in current financial situation due to cancer treatment”
(n = 63, 56.7%), “ability to meet monthly expenses” (n = 59, 50%) and “overall financial
stress” (n = 58, 49.5%) (Table 4-2b).
Out-of-Pocket Expenses
Of 115 study participants responding to the Demographics instrument questions
about monthly out-of-pocket (OOP) expenses associated with cancer treatment given
orally, 66% (n = 78) estimated < $500/month OOP expenses and 34% (n = 40) estimated
> $500/month OOP expenses.
Study participants responded to the types of OOP expenses on both the
Demographics and COST instruments (Tables 4-3, 4-4). From participant responses to
the Demographics instrument question, participants’ OOP expenses included
transportation (gas and parking) (n = 101, 86.3%), over-the-counter medications (n = 67,
57.2%), hotel costs (n = 35, 29.9%), lost wages (n = 23, 19.7%), miscellaneous costs (pet
care, prescription medications, medical marijuana, meals and flights traveling to
appointments, chiropractic/massage) (n = 6, 6.0%) and child care (n = 3 2.6%) (Table 43).
Financial Toxicity and Perception of Distress
Perceptions of high distress due to FT at one week post start of treatment given
orally were 42% (n = 39) and 39% (n = 38) at six months post start of cancer treatment
given orally. Of note, 32% of study participants (n = 44) did not respond to the one week
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after treatment start question. For perception of distress at six months after start of cancer
treatment given orally, 29% of study participants (n = 38) did not respond. (Table 4-4)
From the DT instrument questions about sources of cancer diagnosis-associated
distress (categorized as practical, family, emotional, physical and spiritual problems),
55.7% (n = 64) of the participants cited insurance and financial problems as a source of
distress (Table 4-5.).

Financial Toxicity (FT) and Adherence to Treatment
From study participants responding to the question about adherence to cancer
treatment given orally (n = 136), only 8% of participants (n = 11) reported that they
stopped, interrupted or altered their prescribed cancer treatment given orally (Table 2.).

Study Aim #2

Aim #2
From the study data, describe relationships between sociodemographic and
clinical characteristics and
1)

the participants’ experience of FT (Sub Aim #1)

2)

the participants’ perception of distress (Sub Aim #2)

and
3)

the participants’ adherence to treatment prescribed orally (Sub Aim #3).
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Aim #2: Analysis
The Pearson’s Correlation Coefficient was calculated to evaluate bivariate
correlation between total COST scores at the two time points and the DT scores at the
two time points. (Tables 4-6). The Pearson’s Correlation Coefficient was also calculated
to evaluate any bivariate correlation relationships between COST scores at the two time
points and selected demographic, clinical and financial characteristics—including
adherence to treatment (Tables 4-7 through 4-25). Pairwise comparisons were calculated
for selected demographic variables, for clinical variables and for financial variables
(Tables 4-14, 4-15, 4-16).

Relationships between Financial Toxicity and demographic, clinical and financial
variables
For Aim #2, Sub-Aim 1--to describe relationships between sociodemographic and
clinical characteristics and the participants’ experience of FT--based on Pearson’s
Correlation Coefficient analysis, weak statistically significant relationships were found,
comparing total COST scores at one week and six months after start of cancer treatment
given orally for these variables:
At seven days post start of treatment, COST scores to had a drug plan (r = -.185, p
= .035) (Table 4-9); to affected employment (r= .282, p = .002) (Table- 4-11); and
adherence (r = -.260, p = .003 (Table 4-13). NOTE: Using non-parametric analysis
(Spearman’s Rank Order Correlation), there also was weak correlation, COST Scores at
seven days post start of treatment to OOP costs (rs = .259; p = .005) (Table 4-11).
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At six months post start of treatment, COST scores to had a drug plan (r = -.201, p
= .022) (Table 4-10); to affected employment (r = .326, p < .001) (Table 4-12); and to
adherence (r = .245, p = .005) (Table 4-13). NOTE: Using non-parametric analysis
(Spearman’s Rank Order Correlation), there also was weak correlation, COST Scores at
six months post treatment to OOP costs (rs = .340, p <.001) (Table 4-12)
For demographic variables, correlation coefficients were established between
gender and age (r = .301, p < .001); gender and living status (r = .224, p. = .009); and
education to living status (r= -.264, p = .002) (Table 4-14).
For clinical variables, a moderate correlation coefficient was established between
skipping cancer treatment and taking some of the prescribed non-cancer medications (r =
.600, p = < .001). Weak correlation coefficients were established between lowering the
prescription of non-cancer medications and taking some of the prescribed non-cancer
medications (r = .386, p = <.001); and being covered by insurance and being covered by a
drug plan (r = .219, p = .013) (Table 4-15). In addition, adherence was correlated to
having a drug plan (r = .345, p = <.001) (Table 4-24).
For financial variables, weak correlation coefficients were established between
employed now and employed when started treatment (r = .393, p = < .001); treatment
affected employment and income support (r -= .238, p = .009); income support and gross
income (r = .283, p = .002); gross income and receiving help from pharmaceutical
companies/foundations (r =.354, p = <.001); gross income and percentage of help
received from pharmaceutical companies/foundations (r = .336, p = .001); received help
from pharmaceutical companies/foundations and OOP monthly costs (r = .351, p = .001);
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and percentage help from pharmaceutical companies/foundations and OOP monthly costs
(r = .274, p= .003). (Table 4-16). In addition, adherence was weakly correlated to income
support (r = -.055, p = >.001) and gross income (r = .188, p = .045) (Table 4-25).
A strong correlation coefficient was established for received help from
pharmaceutical companies/foundations and percentage financial help from those noninsurance sources (r = .869, p = .001) (Table-4-16)
For perception of distress and demographic, clinical and financial variables, the
only statistically significant, albeit weak relationship was perception of distress at six
months post start of treatment and the percentage of help from pharmaceutical/foundation
sources (r = .336, p = .001) (Table 4-22).

Relationships between Financial Toxicity and Perception of Distress
For Aim #2, Sub-Aim 2--to describe relationships between the participants’
experience of FT at the two time points and participants’ perception of distress (DT)—
there was no statistically significant relationship calculated in the sample, based on
Pearson’s Correlation Coefficient calculations.

Relationships between Financial Toxicity and Adherence to Treatment
For Aim #2, Sub-Aim 3--to describe the correlation between the participants’
experience of FT and the participants’ adherence to treatment, there was a weak negative
correlation at both time points at one week (r = -.260; p = .003) and six months after start
of cancer treatment given orally (r = -.245; p = .005) (Table 4-13).
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Study Aim #3
Aim #3
Based on the sample data, to explore the likelihood that participant experience of
FT predicts participant perception of distress and non-adherence to the treatment given
orally.

Aim #3: Analysis
From frequency, distribution and univariate analysis of study data, both at one
week and at six months from start of treatment given orally, there were no significant
relationships between total COST scores and Distress Scores at either timepoint: seven
days post start of treatment (r = -.115, p = .276) and at six months post start of treatment
(r - -.085, p = .405). (Table 4-6). Therefore, a logistic regression model for FT level (via
total COST scores) to predict perception of distress could not be calculated.
COST instrument scores were statistically significant related to adherence at
seven days post start of treatment (r = -.260, p = 003) and at six months post start of
treatment (r - -.245, p = .005). For both timepoints, there was a weak negative
correlation, FT to adherence. Since FT and adherence were the only two variables, FT
level (via total COST scores) could not predict adherence to treatment, based on a logistic
regression model (Table 4-13).
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Table 4-1
Participant Characteristics

Table 4-1a
Demographic Characteristics
Gender
Women
Men
Age
50-64 years old
>65 years old
Living Status
Married/domestic partner
Single
Education
<12 the grade, some college
Completed college/grad school

n
136
75
61
136
43
93
136
112
24
136
48
88

%
(55.1%)
(44.9%)
(31.76%)
(68.4%)
(82.4%)
(17.6%)
(35.3%)
(64.7%)
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Table 4-1b
Clinical Characteristics
Cancer Diagnosis
Chronic Lymphocytic Leukemia
Multiple Myeloma
Polycythemia Vera
Essential Thrombosis
Myelofibrosis
Chronic Myelogenous Leukemia,
Prostate, Breast, Lung (1 each)
No response
Oral cancer treatments
For CLL:
Imbrutinib (Imbruvica®)
Venetoclax (Venclexta®)
Acalabrutinib (Calquence®)
For MM
Hydroxyurea (Hydrea)
Lenalidomide (Revlimid®)
For myelofibrosis, polycythemia vera
Ruxolitinib (Jakafi®)
Other oral cancer treatments
Currently Receiving Tx Given Orally
Yes
No
On Treatment for Cancer Given Orally
Stayed on
Temporarily stopped
Never started
Stop other non ca meds
Yes
No
Take some non ca meds
Yes
No
Lower dose non ca meds
Yes
No

n
130
54
34
5
2
7
4

%

24
126

(18.5%)

54
8
3

(42.8%)
(6.3%)
(2.3%)

9
33

(7.1%)
(26.2%)

10
13

(8.0%)
(10.3%)

128
109
19
136
118
4
7
132
5
127
129
5
124
124
8
116

(41.5%)
(26.1%)
( 3.8%)
(1.5%)
(5.4%)
(3.1%)

(85.1%)
(14.8%)
(86.7%)
(2.9%)
(5.1%)
( 3.8%)
(96.2%)
( 4.0%)
(96.1%)
( 6.5%)
(94.0%)
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Table 4-1b
Clinical Characteristics
(continued)
Health Insurance
Yes
No
Insurance Carrier
Private/AARP
Medicare
Medigap
Medicare Advantage (b)
Tri Care, Medicaid (1 each)
Prescription Plan
Yes
No
Prescription Coverage
Part D
Private
Part #, Tri Care (1 each)
Advantage
Responsible for Cancer Cost
<20% of the cost
20-50% of the cost
50-100% of the cost
Co pay (no amount)
Clinical Trials
Grants
Donut, pay % overage
All OOP
Co pay $10/mon
Co pay $25/mon
Co pay $ 40/mon
Co pay $50/mon
Co pay $150/mon
Co pay $200/mon
Co pay $500/mon
Co pay $2000
No response/skipped

n
130
128
2
120
46
32
33
7
2
130
122
8
116
65
47
2
2
121
52
22
6
10
5
3
2
2
1
1
1
1
1
1
1
1
11

%
(98.4%)
( 1.5%)
(39%)
(27%)
(27.5%)
( 6.0%)
( 2.0%)
(94.0%)
( 6.1%)
(56%)
(40.5%)
(1.7%)
(1.7%)
(43.0%)
(18.0%)
(5.0%)
(8.2%)
(4.1%)
(2.4%)
(1.6%)
(1.6%)
(0.8%)
(0.8%)
(0.8%)
(0.8%)
(0.8%)
(0.8%)
(0.8%)
(0.8%)
(9.0%)

Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 =
(5.1%); reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug
plan, n = 6 (4.4%).
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Table 4-1c
Financial Characteristics
Employed now
Fulltime/Part-time
Not Employed
Employed when started ca tx
Yes
No
Tx Affected Employment
Yes
No
Income support
Self
Self/partner/others
Gross income
<$100,000/year
>$100,000/year
Received Pharma/Advocacy
Help
Yes
No
% Support from
Pharma/Advocate Groups
<20%
20-50%
50-100%
Don’t know
Skipped
Monthly OOP costs
<$500/mon
>$500/mon

n
125
32
93
124
67
57
122
42
80
120
28
92
117
82
35
123

%
%
(25.6%)
(74.4%)

57
66
125

(46.3%)
(54.0%)

13
9
34
10
59
118
78
40

(10.4%)
( 7.2%)
(27.2%)
( .8%)
(47.2%)

(54%)
(46%
(34.4%)
(65.6%)
(24.0%)
(75.5%))
(70.0%)
(29.8%)

(66.0%)
(34.0%)

Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); %
help pharma n = 11 (8.1%); Monthly OOP, n =18 (13.2%).
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Table 4-2a
Experience of Financial Toxicity
COST Individual Item Scores
Participant Perception Seven Days after Start of Cancer Treatment Given Orally
Score range: 0-44 [n = responses; (%)]
Overall COST
Score
(n = 119)

I know that I have
enough money in
savings, retirement
or assets to cover
the cost of my
treatment.
(n = 117)

0
Not at
all
27
(23.1%)

Range

Mean

SD

10-39 (29)

25.13

5.154

1
A little bit

2
Somewhat

21(18.0%)

23 (19.7%)

3
Quite a
bit
17
(14.5%)

4
Very
Much
29
(24.8%)

My out-of-pocket
medical expenses
are more than I
thought they
would be.
(n =111)

16
(14.4%)

7 (6.3%)

21 (19%)

29
(26.1%)

45
(41.0%

I worry about the
financial problems
I will have in the
future as a result
of my illness or
treatment.
(n =97)

3 (3.1%)

15 (15.5%)

19 (19.6%)

25
(25.8%)

45
(46.4%)

I feel I have no
choice about the
amount of money I
spend on care.
(n= 118)

2 (2.2%)

8 (6.8%)

19 (16.1%)

24
(20.3%)

65
(55.1%)

67
Table 4-2a
Experience of Financial Toxicity
COST Individual Item Scores
Participant Perception Seven Days after Start of Cancer Treatment Given Orally
Score range: 0-44 [n = responses; (%)]
(continued)
I am frustrated that I
cannot work or
contribute as much
as I usually do.
(n =114)

30
(26.3%)

13
(11.4%)

22
(19.3%)

13
(11.4%)

36
(32.0%)

I am satisfied with
my current financial
situation. (n=117)

38
(32.4%)

16
(13.7%)

29
(24.8%)

20
(17.0%)

14
(12/0%)

I am able to meet
my monthly
expenses. (n =115)

14
(12.2%)

7 (6.1%)

34
(29.6%)

25
(21.7%)

35
(30.4%)

I feel financially
stressed. (n = 116)

22
(18.9%)

12
(10.3%)

29
(25.0%)

21
(18.1%)

32
(27.6%)

I am concerned
about keeping my
job and income,
including work at
home. (n = 107)

26
(24.3%)

13
(12.1%)

20
(18.7%)

18
(16.8%)

30
(28.0%)

My cancer or
treatment has
reduced my
satisfaction with my
present financial
situation. (n= 118)

9 (7.6%)

19
(16.1%)

21
(17.8%)

23
(19.5%)

46
(39.0%)

I feel in control of
my financial
situation.
(n = 116)

24
(20.6%)

26
(22.4%)

33
(28.4%)

23
(19.8%)

10 (8.6%)

COST = Comprehensive Score Financial Toxicity
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Table 4-2b
Experience of Financial Toxicity
COST Individual Item Scores
Participant Perception Six Months after Start of Cancer Treatment Given Orally
Score range: 0-44 [n = responses; (%)]
Total COST Score

Range

Mean

SD

(n = 119)

8-39 (31)

25.17

5.614

0
Not at
all
29 (25%)

1
A little
bit
19
(16.3%)

My out-of-pocket
medical expenses
are more than I
thought they would
be.
(n = 116)
I worry about the
financial problems
I will have in the
future as a
result of my illness
or treatment
(n =116)

9 (7.8%)

17
(14.6%)

6 (5.1%)

I feel I have no
choice about the
amount of money I
spend on care.
(n = 115)

2 (1.7%)

I know that I have
enough money in
savings, retirement
or assets to cover
the cost of my
treatment.
(n = 116)

2
Somewhat

3
Quite a
bit
21
(18.1%)

4
Very
Much
21
(18.1%)

21 (18.1%)

26
(22.4%)

43
(37.0%)

13
(11.2%)

17 (14.6%)

20
(17.2%)

60
(51.7%)

3 (2.6%)

18 (15.7%)

20
(17.4%)

72
(62.6%)

26 (22.4%)
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Table 4-2b
Experience of Financial Toxicity
COST Individual Item Scores
Participant Perception Six Months after Start of Cancer Treatment Given Orally
Score range: 0-44 [n = responses; (%)]
(continued)
I am frustrated that
I cannot work or
contribute as much
as I usually do.
(n = 116)

29 (25%)

18
(15.5%)

22
(18.9%)

14
(12.0%)

33
(28.4%)

I am satisfied with
my current financial
situation. (n = 118)

38
(32.2%)

9 (7.6%)

39
(33.1%)

18
(15.3%)

14
(11.9%)

I am able to meet
my monthly
expenses
(n = 118)

9 (7.6%)

20
(17.0%)

30
(25.4%)

25
(21.2%)

34
(28.8%)

I feel financially
stressed. (n = 117)

16
(13.7%)

16
(13.7%)

27
(23.0%)

18
(15.4%)

40
(34.1%)

I am concerned
about keeping my
job and income,
including work at
home.
(n = 113)

40
(35.4%)

13
(14.4%)

17
(15.0%)

14
(12.4%)

29
(25.7%)

My cancer or
treatment has
reduced my
satisfaction with my
present financial
situation. (n = 111)

14
(12.6%)

16
(14.4%)

18
(16.2%)

17
(15.3%)

46
(41.4%)

I feel in control of
my financial
situation.
(n = 117)

25
(21.4%)

20
(17.0%)

31
(26.4%)

23
(19.7%)

18
(15.4%)

COST = Comprehensive Score Financial Toxicity

70
Table 4-3
Out of Pocket (OOP) Expenses
Responses to Demographics Survey
(Participants responding: n = 117)
Transportation
Hotel
Lost wages
Child care
OTC meds
Other:
Pet care
Prescription meds
Medical Marijuana
Meals when travelling
Flights
Chiropractor/massage

n
101
35
23
3
67

%
86.3%
29.9%
19.7%
2.6%
57.2%

1
1
1
1
1
1

<1%
<1%
<1%
<1%
<1%
<1%

Table 4-4
Distress Thermometer
(0-10 score)
Levels of Distress
@ 1 week
Post Start of
Treatment

Low distress (1-4)
Medium distress
(5-7)
High distress (8-10)

n
92
32
15
39

%

@ 6 months
Post start of
Treatment

(35%)
(16%)

n
97
39
20

%
(40%)
(21%)

(42%)

38

(39%)

Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%); 6
mons post start of tx, n = 39 (29%).
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Table 4-5
Perceived Stresses
Responses to Distress Thermometer Instrument
(Participants responding = 115)
n
Practical Problems
Child Care
Housing
Insurance/Financial
Transportation
Treatment Decisions
Family Problems
Dealing with children
Dealing with partner
Ability to have children
Family health issues
Treatment Decisions
Emotional Problems
Depression
Fears
Nervousness
Sadness
Worry
Loss of Interest in usual
activities
Spiritual/Religion

%

1
14
64
18
27

<1%
12.1%
55.7%
15.7%
23.5%

9
28
4
41
44

7.8%
24.3%
3.5%
35.7%
38.3%

53
66
39
54
82
58

46.1%
57.4%
34.0%
47.0%
71.3%
50.4%

11

9.6%

n
Physical Problems
Appearance
Bathing/Dressing
Breathing
Changes in urination
Constipation
Diarrhea
Eating
Fatigue
Feeling swollen
Fevers
Getting around
Indigestion
Memory/concentration
Mouth sores
Nausea
Nose dry/congested
Pain
Sexual
Skin dry/itchy
Sleep
Substance use
Tingling in hands/feet
Other
Leg cramps
Skin Cancer
Caregiver for Family
Infections
Hot/Cold
Taste of Food
Falling
Skin Eruptions/Rash
Arthralgia

%

53
8
27
17
33
41
34
74
31
8
37
37
64
13
29
35
59
28

48.1%
7.0%
23.5%
14.8%
29.0%
35.7%
30.0%
64.3%
27.0%
7.0%
32.1%
32.1%
55.7%
11.3%
25.2%
30.4%
51.3%
24.3%

61
66
7
47

53.0%
57.4%
6.1%
40.1%

6
1
1
3
1
1
1
4
1

5.2%
<1%
<1%
2.6%
<1%
<1%
<1%
3.5%
<1%
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Table 4-6
Correlations between
Total COST Score (Financial Toxicity)
and Total Distress Thermometer Score

Distress
Thermometer
Score
n
p
r

COST Score
@ 7 days post
start of Treatment
(n = 119)

COST Score
@ 6 months post
start of Treatment
(n = 119)

92
.276
-.115

97
.405
-.085

COST = Comprehensve Score Financial Toxicity
r = Pearson’s Correlation
p = significance @ < .05
NOTE: No correlations are significant
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%); 6 mons post
start of tx, n = 17 (8.8%)
Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%); 6
mons post start of tx, n = 39 (29%)
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Table 4-7
Correlations between
Demographic variables to COST (Financial Toxicity) Scores
(@ Seven Days After Start of Treatment)
(n =117)

n
p
r

Gender

Age

136
.335
.083

136
.509
.057

Living
status
136
.599
-.046

COST = Comprehensive Score Financial Toxicity
r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%)

Education
136
.771
-.025
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Table 4-8
Correlations between
Demographic variables and COST (Financial Toxicity) Scores
(@ Six Months After Start of Treatment)
(n =117)

n
p
r

Gender

Age

136
.207
.109

136
.332
.084

Living
status
136
.829
-.019

Education

COST = Comprehensive Score Financial Toxicity
r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: COST scores 6 mons post start of tx, n = 17 (8.8%)

136
.956
.005
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Table 4-9
Correlations
Clinical Variables to COST (Financial Toxicity) Scores
(@ Seven Days After Start of Treatment)
(n =117)
Skipped
Treatment
n
p
r

136
.249
-.101

Stopped
Take some
↓ Dose of
Insurance:
other
of other
Other
Medicare
Medications medications Medications
or
Private
132
129
124
130
.106
.504
.429
.366
.142
-.059
-.072
-.080

On Drug
plan
130
.035
-.185*

COST = Comprehensive Score Financial Toxicity
r = Pearson’s Correlation
*Correlation is significant at the 0.05 level (2-tailed)
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%)
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%);
reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug plan, n = 6
(4.4%).
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Table 4-10
Correlations
Clinical Variables to COST (Financial Toxicity) Scores
(@ Six Months After Start of Treatment)
(n = 117)
Skipped
Treatment
n
p
r

136
.243
-.102

Stopped
Take some
↓ Dose of
Insurance:
other
of other
Other
Medicare
Medications medications Medications
or
Private
132
129
124
130
.379
.508
.804
.631
.078
-.059
.023
-.043

On
Drug
plan
130
.022
-.201*

COST = Comprehensive Score Financial Toxicity
r = Pearson’s Correlation
*Correlation is significant at the 0.05 level (2-tailed)
Missing data: COST scores 6 mon post start of tx, n = 17 (8.8%)
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%);
reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug plan, n = 6
(4.4%).
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Table 4-11
Correlations between
Financial Variables to COST (Financial Toxicity) Scores
(@ Seven Days After Start of Treatment)
(n =117)

n
p
r

Employ
Now

Employed
when start
Tx

Tx affected
employment

Income
Support

Gross
Income

Received
pharma
help

% help
from
Pharma

Monthly
OOP

125
.827
-.020

124
.941
.007

122
.002
.282*

120
.207
-.116

117
.918
-.010

123
.791.
.024

125
.086
-.148

118
.216
.115

p
rs

.005
.259*

COST = Comprehensive Score Financial Toxicity
r = Pearson’s Correlation
rs = Spearman’s Rank Order Correlation
*Correlation is significant at the 0.01 level (2-tailed)
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%)
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 (8.8%); Tx
affected employment, n = 14 (10.3%); Income Support, n = 16 (11.8%); Gross Income, n
= 18 (13.2%); Received pharma help, n = 13 (9.6%); % help pharma n = 11 (8.1%);
Monthly OOP, n =18 (13.2%).
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Table 4-12
Correlations between
Financial Variables to COST (Financial Toxicity) Scores
(@ Six Months After Start of Treatment)
(n =117)

n
p
r

Employ
Now

Employed
when
start tx

Tx affected
employment

Income
Support

Gross
Income

Received
pharma
help

% help
from
Pharma

Monthly
OOP

125
.673
-.038

124
.902
-.011

122
.001
.326*

120
.060
-.172

117
.371
.083

123
.578
-.052

125
.084
-.149

118
.102
.151

p
rs

<.001
.340*

COST = Comprehensive Score Financial Toxicity
r = Pearson’s Correlation
rs = Spearman’s Rank Order Correlation
*Correlation is significant at the 0.01 level (2-tailed)
Missing data: COST scores 6 mons post start of tx, n = 17 (8.8%)
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); %
help pharma n = 11 (8.1%); Monthly OOP, n =18 (13.2%).
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Table 4-13
Correlations between
Total COST Scores (Financial Toxicity)
and Adherence
COST Score
@ 7 days post
start of Treatment

COST Score
@ 6 months post
start of Treatment

119
.003
-.260

119
.005
-.245

Adherence
n
p
r

COST = Comprehensve Score Financial Toxicity
r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: Correlations are significant
Missing data: Adherence, n = 8 (5.9%)
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%); 6 mons
post start of tx, n = 17 (8.8%)

Table 4-14
Pairwise Correlation Demographic Variables
(n = 136)
Gender
Gender
Age
Living
status
Education

1
.301*
(<.001)
.224*
(.009)
-.047
(.584)

Age

Living
status

Education

1
1.56
(0.69)
.058
(.504)

1
-.264*
(.002)

1

* Correlation is significant at the 0.01 level (2-tailed)
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Table 4-15
Pairwise Correlation Clinical Variables
(n = 136)
Skipped
Treatment

Stopped
other
Medications

Take some
of other
medications

↓ Dose of
Other
Medications

Skipped
Treatment

1

Stopped
Other
meds
Take
some of
other
Meds
↓Dose of
Other
Meds
Type
Insurance

.067
(.451)

1

.600**
(<.001)

.167
(.060)

1

.145
(.107)

.158
(.083)

.386**
(<.001)

1

-.088
(.322)
0.21
(.810)

-.065
(.466)
-0.52
(.559)

.015
(.870)
-.052
(.558)

.104
(.255)
-.074
(.415)

On Drug
Plan

Insurance:
Medicare
or
Private

On
Drug
Plan

1
.219*
(.013)

1

* Correlation is significant at the 0.05 level (2-tailed)
** Correlation is significant at the 0.01 level (2-tailed)
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%);
reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug plan, n = 6
(4.4%)
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Table 4-16
Pairwise Pearson’s Correlation: Financial Variables

n=
Employed
Now
Employed
when Start
Tx
Tx Affected
Employment
Income
Support
Gross
Income
Received
Pharm Help
% Help
from
Pharma
Monthly
OOP

Employed
Now

Employed
when
Start Tx

Tx
Affected
Employ
ment

Income
Support

Gross
Income

125
1

124

122

120

.393**
(<001)

1

.122
(.181)
-.047
(.610)
-.030
(.751)
.077
(.402)
.024
(.786)

-.096
(.296)
-.091
(.323)
.056
(.549)
.023
(.801)
.024
(.790)

1
.238**
(.009)
-200*
(.031)
-.054
(.554)
.037
(.686)

1
.283**
(.002)
.152
(.099)
.165
(.072)

1

.068
(.468)

.012
(.896)

-.051
(.585)

.049
(.603)

.108
(.251)

117

.354**
(<.001)
.336**
(<.001)

Receive
d
Pharm
a Help

% Help
from
Pharma

Monthly
OOP

123

125

118

1
.869**
(<.001
)
.351**
(.001)

1
.274**
(.003)

1

* Correlation is significant at the 0.05 level (2-tailed)
** Correlation is significant at the 0.01 level (2-tailed)
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 (8.8%); Tx
affected employment, n = 14 (10.3%); Income Support, n = 16 (11.8%); Gross Income, n
= 18 (13.2%); Received pharma help, n = 13 (9.6%); % help pharma n = 11 (8.1%);
Monthly OOP, n =18 (13.2%).
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Table 4-17
Correlations Between
Demographic Variables and Distress Thermometer Scores
(@ Seven Days after Start of Treatment)
(n = 92)

n
p
r

Gender

Age

136
.889
-.015

136
.913
-.012

Living
status
136
.395
-.090

Education
136
.389
.091

r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: Distress Thermometer: 7 days post start of tx, n = 44
(32.3%).
Table 4-18
Correlations Between
Demographic Variables to Distress Thermometer Scores
(@ Six Months After Start of Treatment)
(n = 97)

n
p
r

Gender

Age

136
.380
.090

136
.484
.072

Living
status
136
.558
-.060

Education
136
.317
.103

r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: Distress Thermometer: 6 mons post start of tx, n = 39
(29%).
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Table 4-19
Correlations between
Clinical Variables and Distress Thermometer Scores
(@ Seven Days After Start of Treatment)
(n = 92)
Skipped
Treatment
n
p
r

136
.364
.096

Stopped
Take some
↓ Dose of
Insurance:
other
of other
Other
Medicare
Medications medications Medications
or
Private
132
129
124
130
.306
.515
.189
.910
.109
.070
.144
-.012

On
Drug
plan
130
.897
.014

r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%)
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%);
reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug plan, n = 6
(4.4%)
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Table 4-20
Correlations between
Clinical Variables and Distress Thermometer Scores
(@ Six Months After Start of Treatment)
(n = 97)
Skipped
Treatment
n
p
r

136
.254
.118

Stopped
Take some
↓ Dose of
Insurance:
other
of other
Other
Medicare
Medications medications Medications
or
Private
132
129
124
130
.269
.267
.717
.928
.115
.115
.039
.009

On
Drug
plan
130
.452
.078

r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: Distress Thermometer: 6 mons post start of tx, n = 39 (29%)
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%);
reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug plan, n = 6
(4.4%).
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Table 4-21
Correlations between
Financial Variables to Distress Thermometer Scores
(@ Seven Days After Start of Treatment)
(n = 92)

n
p
r

Employed
Now

Employed
when
Start Tx

Tx Affected
Employment

Income
Support

Gross
Income

Received
Pharma
Help

% Help
from
Pharma

Monthly
OOP

125
.441
.084

124
.611
.055

122
.360
-.100

120
.168
.152

117
.773
-.032

123
.052
.210

125
.165
.230

118
.612
.057

r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%)
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 (8.8%); Tx
affected employment, n = 14 (10.3%); Income Support, n = 16 (11.8%); Gross Income, n
= 18 (13.2%); Received pharma help, n = 13 (9.6%); % help pharma n = 11 (8.1%);
Monthly OOP, n =18 (13.2%).

86
Table 4-22
Correlations between
Financial Variables to Distress Thermometer Scores
(@ Six Months after Start of Treatment)
(n = 97)

n
p
r

Employed
Now

Employed
when
start Tx

Tx Affected
Employment

Income
Support

Gross
Income

Received
Pharma
help

% Help
from
Pharma

Monthly
OOP

125
.953
-.006

124
.909
.012

122
.939
.008

120
.305
.111

117
.861
.019

123
.069
.193

125
<.001
.336*

118
.358
-.100

r = Pearson’s Correlation
* Correlation is significant at the 0.01 level (2-tailed)
Missing data: Distress Thermometer: 6 mons post start of tx, n = 39 (29%)
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); %
help pharma n = 11 (8.1%); Monthly OOP, n =18 (13.2%)
Table 4-23
Correlations between
Demographics Variables and Adherence
(n = 128)

n
p
r

Gender

Age

136
.905
-.011

136
.852
-.017

Living
status
136
.257
.101

Education

r = Pearson’s Correlation
Correlation is significant at the 0.05 level (2-tailed)
NOTE: No correlations are significant
Missing data: Adherence: n = 8 (5.9%)

136
.671
.038

87

Table 4-24
Correlations Between
Clinical Variables and Adherence
(n = 128)
Skipped
Treatment
n
p
r

136
.006
.243*

Stopped
Take some
↓ Dose of
Insurance: On
other
of other
Other
Medicare Drug
Medications medications Medications
or
plan
Private
132
129
124
130
130
.756
<.001
.794
.934
<.001
.028
.368*
-.024
.007
.345*

r = Pearson’s Correlation
* Correlation is significant at the 0.01 level (2-tailed)
Missing data: Adherence: n = 8 (5.9%)
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 =
(5.1%); reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug
plan, n = 6 (4.4%).
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Table 4-25
Correlations Between
Financial Variables and Adherence
(n = 128)

n
p
r

Employ
Now

Employed
when start
tx

Tx
affected
employ
ment

Income
Support

Gross
Income

Received
pharma
help

% Help
from
Pharma

Monthly
OOP

125
.583
-.050

124
.153
.131

122
.786
.025

120
<.001
-.055**

117
.045
.188*

123
.161
.080

125
.051
.173

118
.351
-.088

r = Pearson’s Correlation
* Correlation is significant at the 0.05 level (2-tailed)
** Correlation is significant at the 0.05 level (2-tailed)
Missing data: Adherence: n = 8 (5.9%)
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); %
help pharma n = 11 (8.1%); Monthly OOP, n =18 (13.2%).
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CHAPTER 5
DISCUSSION

Introduction

This chapter presents a discussion of a descriptive, cross-sectional study about
cancer patients and their financial toxicity (FT) experience and whether that experience
affected their level of distress or adherence to treatment. This chapter provides a
scholarly context about the study’s results, describing the participants, their FT
experience and relationships among FT-associated variables, perception of distress and
adherence to prescribed cancer treatment given orally.
The study’s data were collected on-line from 136 participants, who were members
of the patient education/advocacy community, Patient Power®. Participants were selfidentified as diagnosed with a malignancy and prescribed a cancer treatment given orally.
Participants completed three study instruments to better describe themselves and their FT
experience: a Demographics Questionnaire, the Comprehensive Score for Financial
Toxicity (COST) and the Comprehensive Cancer Network (NCCN) Distress
Thermometer (DT).
Healthcare Costs
The participants in this study confirm what is known in clinical practice--that the
challenges associated with FT affect whether patients can maintain their health care
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coverage (Conway, 2019; Carrera, Kantarjian & Blinder, 2018; Warsame et al., 2018;
Goldstein, 2017; KFF, 2017).
The burden of FT includes--but is not limited to--access to care, coverage for
care, maintaining sources of income and the impact of FT on interpersonal relationships
(Collado & Brownell, 2019; Salsman, Bingen, Barr & Freyer, 2019; Thom & Benedict,
2019; Honda et al., 2018; Knight et al., 2018; Peppercorn, 2017).
The experience of FT is especially burdensome for individuals diagnosed and
treated for cancer (NCI, 2019; Mohmmed & El-sol, 2018; Winkfield et al., 2018; Shen,
Zhao, Liu & Shih, 2017). As experienced by cancer patients, the focus about FT may be
due to the disruptive impact of cancer on the patient (Allcott et al., 2019; Yabroff, et al.,
2019), the high cost of treatments (Cole, Jazowski & Dusetzina, 2019; Farano, &
Kandah, 2019; Giuliani & Bonetti, 2019; Tran & Zafar, 2018; Truong et al., 2019;
Prasad, de Jesus & Mailankody, 2017) and the long-term impact that FT has on cancer
patients and their caregivers (Banegas et al., 2019; Bradley, 2019; Cole et al., 2019;
Goldstein, 2017).

FT and Study Results
Demographics
This study explored the impact of FT on a sample group of cancer patients,
prescribed treatments given orally. The majority of participants had cancer diagnoses
associated with standard-of-care treatments that were especially high in cost; the majority
of participants were diagnosed with the chronic hematologic malignancies myelogenous
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leukemia (CLL) and malignant myeloma (MM) (Hilal, Betcher & Leis, 2018; Schneider,
Steinbrecher & Stilgenbauer, 2019). For three-months of treatment for these diagnoses,
the range of cost (without insurance coverage, co-payments, deductibles, discounts or
other factors affecting the cost of treatment) is $15,000-$50,000 (B. Chan, personal
communication, October 10, 2019).
As documented in other studies about patients diagnosed with chronic
hematologic malignancies, these study participants received relatively new treatments,
representing treatment breakthroughs (Farano & Kandah, 2019; Hilal et al., 2018). For
these study participants as with others diagnosed with these hematologic malignancies,
their disease is considered a chronic condition, so they can be on treatment for a long
time (Schneider et al., 2019; Peppercorn, 2017). Considered standard treatments for
study participants’ malignancies, the most frequently reported treatments were imbrutinib
(Imbruvica®), lenalidomide (Revlimid®) and ruxolitinib (Jakafi®) (Schneider et al.,
2019; Hilal et al., 2018).
Moreover, over time, when one treatment becomes ineffective, providers may
choose to switch treatments, once again with the option of prescribing treatments with
relatively new FDA approvals (Farano & Kandah, 2019; Giuliani & Bonetti, 2019).
Therefore, additional new treatments for these chronic hematologic malignancies can be
costly (Cole et al., 2019; Truong et al., 2019). In addition, new treatments (in oral
formulations) are early in their FDA approval period so are at high cost, since
pharmaceutical companies want to recoup the cost of drug development (Banegas et al.,
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2019; Califf & Slavitt, 2019; Collado & Brownell, 2019; Giuliani & Bonetti, 2019; TayTeo, Ilbawi, & Hill, 2019; Truong et al., 2019; Yabroff et al., 2018; Prasad et al., 2017).
In this study, the sample population of participants was older, well educated, with
stable social supports and means or strategies to pay for their treatments. The majority of
participants in this study were covered by adequate insurance or had supplemental health
care insurance policies. This study’s overall participant profile matches a significant
cohort of the CLL and MM patient population, who have found ways to continue on their
long-term treatments (Allcott et al., 2019; Yabroff et al., 2018; Schneider et al., 2019).
More women than men were represented in the study sample (women: n =75,
51.1%; men: n = 61, 44.9%). With actuarial tables confirming that women live longer
than men, women’s FT experience may be perceived as more acute or at a higher level.
This more profound female FT experience may be due to more prolonged financial stress;
that stress can build due to age and be exacerbated by less than adequate or no health
insurance coverage (Shen, et al., 2017; Gordon et al., 2017).
The overwhelming majority of the study’s sample population did not skip cancer
treatments given orally due to FT. In addition, participants reported that they rarely
adjusted prescribed non-cancer medications to maintain and pay for their cancer
treatment. This was in keeping with what has been published about FT experienced by
cancer patients and whether they adjusted their cancer therapy so they could stay on
treatment (Renner, Burotto & Rojas, 2019; Knight et al., 2018; Murphy et al., 2018;
Schiffer, 2018).
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Two thirds of the study’s participants reported gross income of <$100,000/year
with the remaining third reporting gross income >$100,000/year. (In 2017, the average
median household income in the U.S. was projected at $57,652 (US Census Bureau,
2019).
For the general population of cancer participants receiving treatments given
orally, not all cancer patients have the option of receiving treatment given orally or the
means to pay for new cancer treatments in oral form (Hilal et al., 2018).

Thus, this

study population benefitted from higher gross incomes, insurance coverage that, in
general, paid for the cost of their treatments and/or pharmaceutical company-funded
programs, which helped cover their treatment expense. These results suggest that this
study’s sample population may not be representative of the experience of other cancer
participants treated with high-cost cancer treatments (Farano & Kandah, 2019). But this
study’s results do suggest that the factors of adequate insurance, access to treatment
support (from pharmaceutical companies and foundations) and an adequate or
temporarily interrupted income stream (employment) mitigate the impact of FT when
patients are prescribed high-cost treatments (Macmillan, 2019, Shen et al., 2017)
FT Experience
This study’s participants experienced various levels of FT and at various times, as
documented by the COST instrument scores and specific responses to the COST
instrument questions. In this study, approximately one third of participants reported their
perception of FT was quite a bit or very much, based on COST scores at both seven days
post start of treatment and six month post start of treatment.
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These results concur with other studies of cancer patients and FT. For studies that
used the COST instrument to further describe and clarify the FT experience, those studies
reported that certain cancer patients experienced higher levels of FT during some period
of their cancer treatment (Bouberhan et al., 2019; Ezeife et al., 2019; Ferrell et al., 2018;
Honda et al., 2018).
Of note in this study, study participants were asked about their perceptions of FT
at two timepoints, which other studies have not explored in their study designs. For this
study, the level of total FT scores was slightly higher six-months after treatment began
compared to seven days after treatment began. These findings concur with other studies,
which report that cancer patient FT can increase over time, especially with the stress of
continuing, high-cost therapies, as well as the chronic impact of a cancer diagnosis on
daily life (Thom & Benedict, 2019; Carrera et al., 2018; Shen et al., 2017).
In this study from the COST instrument, these specific FT responses were scored
higher at both the seven day and six month post start of treatment timepoints: “Feel no
choice about cost of care”, “worry about future financial problems due to illness”,
“higher than anticipated out of pocket medical expenses”, “reduced satisfaction in current
financial situation due to cancer treatment”, “ability to meet monthly expenses” and
“overall financial stress”. These responses were in keeping with findings from other
studies about FT and the cancer patient experience (Ezeife et al., 2019; Carrera et al.,
2018; Honda et al., 2018).
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Out of Pocket Expenses for Treatment
About two thirds of study participants reported OOP costs < $500/month with the
remaining third of participants reporting OOP costs >$500/month. Studies have reported
that OOP health insurance co-pays and deductibles are rising (KFF, 2017). For cancer
patients, OOP costs can be extensive and unpredictable (Conway, 2019).
Participants in this study also concur that transportation costs (gas and parking)
are the most often cited OOP costs related to cancer treatment (Leopold et al., 2019;
Rosenzweig et al., 2019). Study participants also noted they experienced higher copays
and deductibles associated with their insurance coverage and treatment (Conway, 2019;
KFF, 2017). Other OOP costs from this study’s participants (loss of income, child care,
over-the-counter medications), are similar to OOP costs reported in other FT studies
(Leopold et al., 2019; NCI, 2019; Buttner et al., 2018).
Financial Support for Treatment
For study participants responding about receiving financial support for treatment
from pharmaceutical, foundation or other non-insurance sources, they were generally
split between those who received support (n = 57, 46.3%) and those who did not receive
support (68, 54.0%). Cancer patients’ source of additional financial support and how
much financial support goes to the cost of treatment have not been rigorously studied
(MacMillian, 2019). In this study, approximately half of study participants did not
respond to the question about the percentage of financial support received from noninsurance sources.

Still in clinical practice, pharmaceutical, foundation or other non-
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insurance sources significantly augment the OOP expenses of cancer treatment when
patients’ insurance coverage does not cover the cost of treatment (MacMillan, 2019).
In this study for participant perception of distress related to demographic, clinical
and financial variables, the only statistically significant relationship was perception of
distress at six months post start of treatment and the percentage expense supported by
pharmaceutical companies or foundations (r = .336, p = .001). This suggests that over
time, the level of distress can be affected by the level of pharmaceutical or foundation
financial support (MacMillan, 2019).
Distress Experience
More than a third of study participants reported high distress due to FT at both
one week post start of treatment and at six months post start of treatment. Distress due to
just FT is difficult to measure, when the cancer experience in its entirety is stressful.
For this study at the two timepoints, there was no statistically significant
relationship established between FT and participants’ perception of distress. Still other
studies concur that FT is a prevalent source of distress for cancer patients so FT has
clinical significance (Ezeife et al., 2019; Thom & Benedict, 2019; Carrera et al., 2018).
Worth noting in this study at both timepoints, almost a third of participants did
not respond to the study’s distress instrument. This, once again, suggests that identifying
FT as a distinct source of stress to cancer patients is difficult (Thom & Benedict, 2019).
In this study, the non response to the distress instrument may be due to the participant’s
own difficultly in separating FT-related stress from the participant’s general distress
about the cancer experience (Rosenzweig et al., 2019; Thom & Benedict, 2019). It may
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also be due to not wanting to respond to an instrument measuring distress (Vanhoose et
al., 2015; Mitchell, 2007).
Adherence to Treatment
Most study participants reported that they adhered to their prescribed cancer
treatment given orally and did not stop, interrupt or alter their prescribed treatment
regimen because of FT. These findings are in keeping with studies that show despite the
stress brought on by FT, treatment adherence is high (Gupta et al., 2019). In this study,
COST instrument scores, representing FT, had a weak negative correlation related to
adherence at seven days post start of treatment (r = -.260, p = 003) and at six months post
start of treatment (r - -.245, p = .005). But in this study due to the sample size, FT could
not be statistically established as a predictor of adherence.
As identified in other studies to maintain treatment adherence, participants in this
study mobilized a multitude of strategies to support adherence: intact and robust health
insurance coverage; coverage from supplemental health insurance policies; drug coverage
plans that cover specialty medications (i.e. new cancer treatments given orally); financial
support from pharmaceutical, foundation or other non-insurance sources to cover
treatment costs; and the ability to adequately cover OOP costs of treatment (sufficient
gross income, sources of regular income) (Cole et al., 2019; Gupta et al., 2019; Taylor,
2019; Rosenzweig et al., 2019, Honda et al., 2018; Knight et al., 2018).
In this study, adherence to treatment was weakly correlated to income support (r =
.005, p = >001) and gross income (r = .045, p = .188).
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FT Relationships
In the context of FT, this study’s findings suggested weak relationships at both
seven days and six months post start of treatment, based on COST scores and whether
participants had a drug plan, whether they were employed and whether they adhered to
treatment. Several studies of cancer patients have identified similar FT-associated
relationships (Schneider et al., 2019; Taylor, 2019; Gilligan, Alberts, Roe & Skrepnek,
2018).
In this study describing participants’ experience of FT and demographic variables,
there were weak relationships associated between gender and age; gender and living
status; and education to living status. These relationships may not be consistent for all
cancer patients and their experience with FT (Thomas et al., 2019).
From participants’ experience with FT and clinical variables, this study suggests
weak relationships between
•

lowering the dose of non-cancer medications and taking some prescribed
non-cancer medications, as prescribed

•

being covered by insurance and being covered by a drug plan

•

adherence to treatment and having a drug plan

•

employed now and employed when started treatment

•

treatment affected employment and income support

•

income support and gross income

•

gross income and receiving help from pharmaceutical
companies/foundations

99
•

gross income and percentage of help received from pharmaceutical
companies/foundations

•

received help from pharmaceutical companies/foundations and OOP
monthly costs

and
•

percentage help from pharmaceutical companies/foundations and OOP
monthly costs.

In this study, a moderate correlation was established between skipping cancer
treatment and taking some prescribed non-cancer medications (r = .600, p = < .001). This
study also indicated a high correlation between pharmaceutical/foundation support and
percentage help offered participants from those sources (r = .869, p = .001);
For all the study’s intra-variable relationships listed above, these relationships
confirm that FT issues are entwined and affect the overall FT experience (Ezeife et al.,
2019; Gupta et al., 2019; MacMillan, 2019; Renner, Burotto & Rojas, 2019; Thomas et
al., 2019; Prasad et al., 2017; Shen et al., 2017).
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Summary: FT and Study Results
This descriptive, cross-sectional study included participants diagnosed with
chronic hematologic malignancies, treated with treatments given orally. Therefore, for
their long-term cancer treatment, these study participants received high-cost cancer
treatments, which affected their experience with FT, distress associated with FT and
adherence to prescribed treatments.
Confirming previous study findings in the literature, this study’s patient
population experienced various levels of FT and at various times. In this study,
approximately one third of the participants reported that FT was quite a bit or very much
both at seven days post start of treatment and six month post start of treatment.
Distress associated with FT can be an issue although FT as a distinct source of
distress was not confirmed in this study. To accommodate issues of FT, study participants
received support from pharmaceutical, foundation or other non-insurance sources. They
also were able to cover the cost of their treatment due to having robust insurance
coverage, adequate income streams and the ability to cover OOP costs.
In this study, despite the patient’s perception of FT at both one week post start of
treatment and at six months post start of cancer treatment given orally, adherence to
cancer treatment was largely not affected.
Finally, this study’s findings concur that the FT experience for cancer patients is
associated with many variables, which have intertwined relationships (Ezeife et al., 2019;
Gupta et al., 2019; Thomas et al., 2019; Carrera et al., 2018; Prasad et al., 2017).
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Limitations
This study’s findings have several limitations; these limitations affect whether the
findings are applicable or generalizable to the FT experience of all cancer patients.
Study Design
Study limitations included the study design.

The study was a descriptive, cross-

sectional design study, seeking participants via a convenience sample from one on-line
cancer patient education/advocacy group site. The participants were self-described as
diagnosed with cancer and prescribed treatment given orally. Because of the study
design, the profile of each participant could not be verified so the study’s data,
representing the experience of cancer patients and FT, also could not be verified.
The study requested that participants respond to the study’s three measurement
instruments, relaying their perceptions about FT at two timepoints. Choosing these
particular timepoints was arbitrary. In addition, study data relied on participants
determining perceptions from their past, which could have been inexact, exaggerated
and/or reliant on interpretations from vague memories.
Sample Population
In general, the participant sample was small in number, older, highly educated,
adequately insured, benefitted from stable social supports, had adequate income streams
and diagnosed with a chronic cancer diagnosis. The participants were asked to respond
to their experience associated only with their cancer treatment prescribed orally. Because
of their cancer diagnosis and their cancer treatments prescribed orally, those treatments
had higher costs.
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Study participants were English speaking, had access to the internet and were
asked to respond to study questionnaires posing questions about complex concepts—FT
and distress. Although the sample population was recruited anonymously, the
participant responses could have been biased toward what they assumed would be the
outcomes of the study (i.e. everyone suffers from FT; everyone has had an extreme FT
experience.)
Participants in the study were not asked about their culture, ethnicity or sexuality.
Therefore, those characteristics were unknown and so could not be reported. Because
this information was not captured, the interpretations of study findings are limited.
Instruments in Study
The Comprehensive Score for Financial Toxicity (COST) instrument is a
relatively new instrument to measure FT and has been tested valid with advanced cancer
patients (deSouza et al., 2017, 2014). Its reliability and validity as a measurement
instrument has not been studied in many populations with various diagnoses, stages of
disease, treatment side effect profiles and experiences of FT (Bouberhan et al., 2019;
Ezeife et al., 2019; Honda et al., 2018).
The National Comprehensive Cancer Network (NCCN) Distress Thermometer
(DT) has been widely studied and used to evaluate distress in cancer patients. However,
its reliability and validity as an instrument when administered online has not been
thoroughly tested (NCCN, 2018).
The study’s Demographics Questionnaire, administered on-line and focused on
categorial responses to questions, was developed so it would be easy for participants to
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complete. There was no reliability or validity testing of the questionnaire. Because the
questionnaire requested broad responses to sensitive topics (gross income, specifics about
the experience of FT, financial support to cover the costs of treatment), captured study
data may be too broad to determine FT distinctions related to the FT experience,
demographic and clinical variables, FT association with distress and FT association with
adherence to treatment. In addition, this study’s instruments did not capture the patient’s
self-assessment of severity or stage of illness, which would impact responses for FT,
distress and adherence.
In relation to the study’s three instruments, participants may have been reluctant
to complete all or part of the instruments’ questions since some questions were about
sensitive topics. Among those sensitive topics was the experience with FT, the ability to
pay for treatment, the need to secure financial resources to supplement the expense of
treatment and distress during cancer treatment.
Clinical Practice Implications
This study results suggest several implications for practice.
Despite FT as a relatively newly-recognized stress in the cancer patient’s
experience, FT as a form of stress can occur in varying degrees, depending on the patient
and caregiver circumstances (Thomas et al., 2019; Carrera et al., 2018). The ability for
the cancer patient and caregivers to function depends on a combination of physical,
psychosocial and spiritual factors (Knight et al., 2018). When and whether FT affects
patients is due to the dynamic, complex experience of cancer as a disease, as well as the
experience of being treated for cancer (Thomas et al., 2019). With FT contributing to
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patient and caregivers stress, FT affecting care may be anticipated (Rosenzweig et al.,
2019; Thom & Benedict, 2019; Carrera et al. 2018). It may also be addressed with the
expertise of those who can problem-solve the patient’s healthcare financial status (Carr &
Rosato, 2019; Sherman & Fessele, 2019; Berry et al., 2018). And just as with other
stresses, FT can be managed as part of the plan of care (NCCN, 2018).
As with all stresses associated with the care of cancer patients and caregivers, the
nurse-- as a member of the interdisciplinary care team--can make a significant impact to
address FT.
Nursing Care
Assessment. As a standard of care, FT is becoming a component of the nurse’s
clinical assessment (Carr & Rosato, 2019).
As a part of a clinical assessment initiated or continued by the clinical nurse, FT
assessment does not need to be overly intrusive or involved. The assessment can include
a few questions to start a conversation about FT issues or continue that conversation as
treatment proceeds. Then the conversation can continue as the plan of care continues or
changes (Carr & Rosato, 2019).
The foundation for a FT-associated clinical assessment begins with questions
similar to those listed in the COST instrument (deSouza et al., 2017, 2014). At its
foundation, a nurse-initiated FT assessment generates information from the patient about
the patient’s health insurance, sources of income, OOP costs and the physical and
psychological effects of FT (Katz, 2018).
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Referrals. Any effective care of patients experiencing FT requires support and
counsel from those who have expertise about healthcare coverage and financial issues
(Sherman & Fessele, 2019; Berry et al., 2018). In academic healthcare centers,
comprehensive cancer centers and large health care systems, that expertise has become
available to patients through financial counselors and/or specially-trained nurse
navigators, social workers and lay patient navigators (Carr & Rosato, 2019).
Nurses who provide direct care to patients can be the conduit to financial
counselors (Nipp, Sonet & Guy, 2018). As members of the interdisciplinary team,
nurses can best care for patients by knowing available resources, connecting the patient
with effective financial-support resources and ensuring that patients receive information,
support and direction so that FT is addressed (Sherman & Fessele, 2019).
Support. In relation to the cancer patient’s care plan, the nurse remains a reliable
source of support, providing patient education, psychosocial support and strategies for
problem solving (Carr & Rosato, 2019; Thomas et al., 2019; Ferrell et al., 2018) As this
study’s findings suggest, providers who are aware of the patient’s FT issues can better
intervene to provide effective support (Bradley, 2019).
Decision Making
As the study’s results confirm, FT contributes to patients’ uncertainty related to
the cancer diagnosis, treatment plan and life expectancy. Since studies have raised the
visibility of FT as a stress for cancer patients, several decision-making models have been
proposed to open up the discussion about treatment and financially-based pros and cons
about treatment options (Chino et al., 2019; Leopold et al., 2018; Gidwani-Marszowski et
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al., 2018; Bien et al., 2017). These proposed frameworks may support transparency
between providers and patients about treatment options toward shared decisions about
treatment (Nipp et al., 2018).
The role of the provider, opening up the process of decision making, has been
studied, focusing on changing the hierarchy of information, traditionally in the sole
control of the provider. These revised models attempt to shift decision-making to both the
provider and patient, based on the patient’s preferences (Warsame et al., 2019). These
evolving decision-making frameworks intend to broaden treatment discussions—
including issues of the cost of care (Dine, Masi & Smith 2019; Doshi et al., 2019; Hong,
Matusiak & Schumock, 2018).
However, these decision-making frameworks are limited since providers often do
not know the cost of the therapies they recommend (Farano & Kandah, 2019). And
providers typically do not have access to basic information about the patient’s finances
related to treatment decisions. In general, providers do not know the patient’s individual
insurance coverage benefits or options for supplemental financial support for care (Dine
et al., 2019). Moreover, there is no guarantee that the patient understands his or her
health care financial information or status (Nipp et al., 2018).
Frameworks and decision-making tools focus on patient choice (Seidman, Masi,
Gomez-Rexrode, 2019; Bien et al., 2017), value of treatment (Doshi et al., 2019; Leopold
et al., 2019; Gidwani-Marszowski et al., 2018), cost of care (Dine et al., 2019, Truong et
al., 2019; Yu, Eton & Garrison, 2019), patient expectations (Hong et al., 2018)
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information provided (Warsame et al., 2019), or a combination of the above (Doshi et al.,
2019, Gidwani-Marszowski et al., 2018, Hong et al., 2018).
Future Research
This study’s findings suggest directions for future research to better understand
the FT experience, formulate FT standards of care and to establish clinical FT policies
related to the care plan (Thomas et al., 2019). Questions remain about FT and cancer
patients—when it occurs, how best to address it, what resources can be mobilized over
time and how to mitigate the high cost of cancer medications and treatment. What are the
most effective and sensitive clinical interventions that provide patients and their
caregivers with information, support and ways to problem solve? (Berry, Deming &
Danaher, 2018).
Opportunities for FT Research
Among opportunities for FT research are cancer patients at risk for FT (Rupper,
2018), FT challenges they face (Winkfield et al., 2018), patients with limited or
interrupted incomes due to their diagnoses (Allcott et al., 2019; Collado & Brownell,
2019), intense FT flashpoints during the continuum of care (Yu et al., 2019), treatment
protocols that increase FT (Cole et al., 2019) and advocacy strategies (Thomas et al.,
2019).
To address FT experienced by patients and caregivers, nurse researchers—as
members of interprofessional teams—can identify, then investigate interventions that
result in better patient outcomes (Thomas et al., 2019; Mohmmed et al., 2018). These
outcomes suggest that the standard of care requires FT expertise in the plan of care
(Bradley, 2019; Sherman & Fessele, 2019). Studies are needed about the merit of the
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designated financial navigator role (Sherman & Fessele, 2019; Thom & Benedict, 2019;
Berry et al., 2018), financial experts for patients at FT risk (Sherman & Fessele, 2019),
financial expertise to address FT at specific timepoints (Berry et al., 2018), the need for
comprehensive healthcare coverage (Conway, 2019) and strategies to pay for the cost of
care (Cole, et al., 2019; Yu et al., 2019).
Survivorship
Cancer survivors present distinct FT implications (Benagas et al., 2019, Coughlin
& Dean, 2019, Yabroff et al., 2019).

Survivors face FT issues related to extended

treatment costs and sacrifices to pay for long-term or recurrent disease (Chino et al.,
2019; Peppercorn 2017; Prasad et al., 2017). They are challenged to secure adequate
healthcare insurance coverage and pay higher insurance premiums (Coughlin & Dean,
2017; KFF, 2017). They are concerned about their ability to keep working and maintain
an income stream (Pearce et al., 2019). And they need ongoing support and new
resources to access care (Benagas et al., 2019, Pearce et al., 2019, Salsman et al., 2019,
Yabroff, et al., 2019; Zahnd et al., 2019).
Federal Policy and Drug Costs
Despite market forces that affect the cost of drugs in the U.S., the federal
government’s influence over drug prices is significant, related to its ability to establish
price controls or to negotiate prices for a large swath of patients covered by governmentsupported health care (Blumenthal, 2016).
With access to affordable, quality health care remaining a #1 priority of
consumers in the U.S., the high cost of prescription drugs is just one of many health care
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issues requiring a solution (Speaker, 2019). Since the price of drugs in the U.S. can be
twice the cost of drugs in other wealthy countries (Blumenthal, 2016), the public’s call
for legislative remedies is persistent even while effective strategies to navigate barriers
remain elusive (Stone, 2019; Sweeney, 2019; Walter, 2019)
Federal policies that affect drug prices are very complex. The challenge to
decipher policies and determine who or what is influencing the cost of drugs contributes
to the complexity. Specific issues associated with federal policy include questions
regarding how drug prices are determined, which drug prices can be negotiated, the
extent of rate hikes, the transparency of billing and limitations or restrictions on
pharmacy formularies (Horvath, 2018; KFF, 2019; Stone, 2019).
Moreover, momentum to support any given legislative or policy proposal is fluid,
affected by coalitions representing a wide array of players and agendas: health care
facilities, health care providers, consumer advocacy groups, political parties,
pharmaceutical companies and the government itself (Kodjak, 2018; Stone, 2019; Walter,
2019).
Legislative and Regulatory Initiatives
Legislation to impact the cost of drugs is generated by Congress. Legislation
establishes broad, general laws that direct policy. Regulations are generally written and
promulgated by the executive branch to implement and enforce legislation (ISB, 2019).
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Legislation
An example of drug cost legislation proposed in the 116th Congress session of
Congress (2019-2020) is HR-3, The Lower Drug Costs Now Act (Speaker, 2019).
Among the provisions of HR-3 is a requirement to change laws that currently prohibit the
Centers for Medicare & Medicaid Services (CMS) from negotiating prescription drug
prices for its Medicare beneficiaries (Feke, 2019; McCaughan, 2017). For Medicare
beneficiaries, HR-3 proposes that CMS negotiate the price of certain drugs, including
insulin and selected drugs that do not have generic equivalents since the government
already can negotiate prices for federally supported Medicaid programs and the Veterans
Administration (Feke, 2019; McCaughan, 2017). Many of the targeted drugs in HR-3 are
for drugs most commonly prescribed for Medicare beneficiaries.
Another component of HR-3 calls for setting maximum drug price ceilings for
certain drugs and to allow a new framework for cost sharing when drug prices hit a predetermined threshold (Speaker, 2019).
Although HR-3 does not target specialized cancer drugs in the legislation, efforts
to curb specialized cancer drug prices start with winning the battle about sensible drug
pricing for common prescription drugs (Stone, 2019; Sweeny, 2019).
Regulations
In general, regulations that address drug prices are the purview of the U.S.
Department of Health and Human Services (DHHS), specifically through its agencies, the
Centers for Medicare and Medicaid Services (CMS) and the Food and Drug
Administration (FDA) (CMS.gov, 2019; Waxman et al., 2019).
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FDA rules that explicitly impact cancer drugs include those addressing the
development and approval of new drugs, and more specifically patents and exclusivity
rights. The American Association of Clinical Oncology (ASCO), the professional society
of clinical oncologists, has opposed regulations “extending market or data exclusivity
periods” for a wide array of new cancer treatments, classified as small-molecule, generic,
orphan, and biologic drugs (ASCO, 2019). ASCO also has joined other patient advocacy
groups, opposing Pharmacy Benefit Management (PBM) companies (third party
prescription drug administrators), whose initiatives attempt to control cancer treatment
costs but limit the ability of providers to prescribe appropriate and effective treatments
for patients (ASCO, 2019). (In 2017, PBM companies managed prescription benefits for
an estimated 85% of health insurance benefits for those with public and private health
insurance plans (NASEM, 2017).)
The DHHS has also proposed revising regulations associated with improving
transparency of drug costs, so that visibility of those costs would encourage negotiation
and produce fewer surprises to consumers. Those regulations would eliminate bills for
the costs of care that were never discussed or determined before care was rendered.
These efforts have been initiated to establish more rational “Balanced Billing”.
“Balance Billing” usually is defined as billing a patient for the difference between the
total cost of services being charged and the amount the insurance pays. In reference to
high cancer drug costs, revisions in “Balanced Billing” regulations would protect the
patient from exorbitant bills when patients must go out of their insurance network for
care and pay for that non-covered care. For oncology patients, these situations occur
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when their standard of care requires treatment that includes specialized cancer drugs not
covered by their insurance. However once again, progress toward support of revised
regulations has been thwarted by the Courts, who have, to date, agreed with the
pharmaceutical industry argument that revised regulations represent regulatory overreach
(Stone, 2019; Sweeney, 2019).
Federal Policy and Values
So, in the long run, to pass legislation that has any effect on the cost of drugs,
lawmakers--representing the electorate—must deal with what society values. That focus
on values includes what the electorate determines as fair—or even acceptable—as larger
questions loom about a broken, inefficient health care system (Sweeney, 2019). These
questions pit all sides in economic, legal and moral power struggles. And from these
struggles, it remains to be seen what drug cost changes can occur in a partisan political
climate.
Conclusion
The experience of FT is an additional stress to cancer patients and their
caregivers, especially during treatment, but also throughout the continuum of care. The
FT experience has many components, and is distinct for each individual, depending on
the patient’s diagnosis, treatment plan, cost of treatment and clinical and financial factors.
For any given patient when treatment begins and as it continues, FT may affect the
patient’s perception of distress and adherence to treatment.
This study’s findings characterized the FT experience, its timing and possible FT
management strategies. These findings contribute to the ongoing clinical foundation
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about FT, suggesting ways to improve the complex care of cancer patients and their
caregivers.
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Appendix B
Study Blurb
You are invited to be a participant in a research study conducted by Ellen Carr, RN. Ellen is
a clinical oncology nurse. She is also a doctoral student at the Hahn School of Nursing and Health
Science at the University of San Diego (USD).
The Study
The study is about the concept of financial toxicity, which is a term that refers to the
financial consequences of cancer treatment, which may include significant out of pocket (OOP)
costs, loss of income and caregiver burden. The study will help doctors, nurses and other health
care providers better understand financial toxicity when experienced by cancer patients. The study
will include patients like you, who have completed or are taking cancer therapy given orally.
The study involves you completing three surveys a) a demographics survey, b) a survey
about your experience with financial toxicity during or after your cancer treatment, c) a survey
about distress related to your cancer treatment. It will take about 10-15 minutes for you to
complete the surveys on-line.
Inclusion/Exclusion Criteria
The inclusion criteria for participants will be adult patients (21 years or older) who are
Spanish or English speaking, have the ability to read English and have an initial diagnosis of these
malignancies: Breast cancer, head and neck cancer, Hodgkin’s Lymphoma, lung cancer leukemia,
lymphoma, melanoma, multiple myeloma, myloproliferative neoplasms, pancreatic cancer, prostate
cancer. Participants will need to have been prescribed by their oncologist a cancer treatment given
orally as a component of their cancer treatment regimen. The treatment given orally will be been
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prescribed with the patient receiving treatment for at least 4 weeks. The participants’ health
insurance coverage can include private health insurance or coverage by Medicare (Medicare Fee for
Service (FFS), Medigap or Medicare Part C (Advantage).
The exclusion criteria for study participants includes patients who have not been prescribed
cancer treatment given orally (i.e. infusion only; radiation and/or surgery only) and those receiving
in-patient cancer treatment. In addition, excluded study participants will be those covered by
Medicaid or are those without health insurance coverage.
Interested in joining this Study?
If you would like more information about the study, here is a link to more information about
the study: (Web Site #1) You can also contact Ellen Carr, the study investigator, directly at e-mail:
xxxxxxx; phone: xxxxxx.
If you are interested in participating in the study, here is a link to the informed consent for
the study, then links to the surveys for you to complete: (Web Site #2)
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Appendix C
Web Site #1 Content
Study Synopsis
Financial toxicity is an additional stress for patients being treated for cancer. The study is
about the concept of financial toxicity, which is a term that refers to the financial consequences of
cancer treatment, which may include significant out of pocket (OOP) costs, loss of income and
caregiver burden that occur when patients are undergoing treatment. The study will help doctors,
nurses and other health care providers better understand financial toxicity when experienced by
cancer patients.
Oral medications for cancer are particularly expensive. It is expected that more pricey oral
medications will be approved as cancer treatments so there will be more patients who will deal with
the financial toxicity of treatment.
Therefore, Ellen Carr, an oncology nurse and doctoral student at the University of San
Diego is studying financial toxicity and cancer patients who have been treated or are still in
treatment with therapies given orally.
The study will include patients like you, who have completed or are taking cancer therapy
given orally. The Study Purpose and Aims of the study follow:
Study Purpose:
For adult participants who have received or are receiving treatment for hematologic and
solid tumor malignancies given orally, to determine the relationship between participants’
experience of financial toxicity (FT), the participants’ perception of distress, and participants’ selfidentified adherence to prescribed treatments
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Study Aims:
1.

To describe sociodemographic, clinical and financial characteristics, the experience

of FT, perception of the level of distress, and adherence to treatment in a sample of adult
participants who have received or are receiving treatment given orally for hematologic or solid
tumor malignancies.
2.

To examine relationships between participant sociodemographic, clinical and

financial characteristics, participants’ experience of FT, participants’ perception of distress, and
participants’ adherence to treatment.
3.

To explore the likelihood that participant experience of FT predicts participant

perception of distress and non-adherence to treatment given orally.
FAQs about the Study
1) What will I need to do to participate in the study?
The study involves you completing three surveys a) a demographics survey, b) a survey
about your experience with financial toxicity during or after your cancer treatment, c) a survey
about distress related to your cancer treatment. It will take about 10-15 minutes for you to
complete the surveys on-line.
2) Do I need to answer all questions on the surveys?
No. You can only give responses to questions that you choose to answer.
3) Will I be paid to participate in the study?
There is no payment for completing the study surveys
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4) How will I hear about the results of the study?
When the study results are complete and ready to be announced and published, Ellen can let
you know. (You will need to provide your contact information on your informed consent form so
she can contact you.)
Study Investigator’s contact information
If you would like more information about the study, here is a link to more information about
the study: (Web Site #1) You can also contact Ellen Carr, the study investigator, directly at e-mail:
xxxxxxx; phone: xxxxxx.
Instructions to join the Study
If you are interested in participating in the study, here is a link to the informed consent for
the study, then after confirm acceptance of the informed consent, Ellen will contact you via your email with a link to the surveys for you to complete: (Web Site #2)
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Appendix D
Web Site #2 Content

Study Synopsis (repeat from Web site #1)
Financial toxicity is an additional stress for patients being treated for cancer. The study is
about the concept of financial toxicity, which is a term that refers to the financial consequences of
cancer treatment, which may include significant out of pocket (OOP) costs, loss of income and
caregiver burden that occur when patients are undergoing treatment. The study will help doctors,
nurses and other health care providers better understand financial toxicity when experienced by
cancer patients.
Oral medications for cancer are particularly expensive. It is expected that more pricey oral
medications will be approved as cancer treatments so there will be more patients who will deal with
the financial toxicity of treatment.
Therefore, Ellen Carr, an oncology nurse and doctoral student at the University of San
Diego is studying financial toxicity and cancer patients who have been treated or are still in
treatment with therapies given orally.
The study will include patients like you, who have completed or are taking cancer therapy
given orally. The Study Purpose and Aims of the study follow:
Study Purpose:
For adult participants who have received or are receiving treatment for hematologic and
solid tumor malignancies given orally, to determine the relationship between participants’
experience of financial toxicity (FT), the participants’ perception of distress, and participants’ selfidentified adherence to prescribed treatments
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Study Aims:
1.

To describe sociodemographic, clinical and financial characteristics, the experience

of FT, perception of the level of distress, and adherence to treatment in a sample of adult
participants who have received or are receiving treatment given orally for hematologic or solid
tumor malignancies.
2.

To examine relationships between participant sociodemographic, clinical and

financial characteristics, participants’ experience of FT, participants’ perception of distress, and
participants’ adherence to treatment.
3.

To explore the likelihood that participant experience of FT predicts participant

perception of distress and non-adherence to treatment given orally.

Instructions to complete the Informed Consent
Please follow the link to the Informed Consent form:
Informed Consent:
Introduction: You are invited to be a participant in a research study conducted by Ellen Carr, RN.
Ellen is a clinical oncology nurse. She is also a doctoral student at the Hahn School of Nursing and
Health Science at the University of San Diego (USD).
The study is about the concept of Financial Toxicity. Financial Toxicity refers to the
financial consequences of cancer treatment, which may include significant out of pocket (OOP)
costs to you and your family, loss of income and patient and caregiver burden. The study will help
doctors, nurses and other health care providers better understand financial toxicity when
experienced by cancer patients. This study will include patients like you, who have completed or
are taking cancer therapy given orally.
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Purpose of the study:
For patients receiving treatment for hematologic and solid tumor malignancies given orally,
the purpose of this study is to determine the relationship between the patient’s experience of
financial toxicity, the patients’ perception of their level of distress and whether patients went ahead
and took or completed their prescribed therapy given orally.
Procedures:
From an on-line survey that you can complete at your convenience, you will be asked about
your experience with financial toxicity during the period when you were (or still are) taking your
cancer therapy given orally. Specifically, you will be asked to complete three brief surveys about
the financial burden while you are on the therapy, any distress related to the financial burden when
you were on the therapy and if the financial burden caused you to stop taking your therapy or take
part of your therapy. Completing all the questions on the three surveys will take about 10-15
minutes. You can choose to not answer some of the questions.
Potential Risks and Discomforts:
The questions on the survey may cause you to feel sad or mad. You can choose not to
answer any questions. You also may stop answering questions at any time.
Anticipated Benefits to You:
You will not receive any direct benefit from participating in the study. There is no
compensation for participating in this study. However, after completing the survey, you may feel
good about relaying your experiences about the financial burden when you received your therapy.
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Anticipated Benefits to Others:
The study results will help doctors, nurses and other health care providers better understand
financial toxicity when experienced by cancer patients. With that knowledge, ways to lessen the
financial burden for patients and their caregivers can be developed.
Privacy/Confidentiality:
Your responses to the surveys will be kept confidential. This informed consent and any
other identifying information will be kept separate from the survey results. All study information
will be kept in a locked, secured location. Your survey results will be assigned a unique
identification number. Any study identification number assigned to you will only be known by
Ellen, the study investigator, and her dissertation committee; they are the only people who will have
access to your study identification number. Any report of the study results will not identify you by
name or your identification number.
Withdrawal from Study:
Your participation in the study is entirely voluntary. If you participate in the study, your
participation will not affect your current or future cancer care. You can withdraw from the study at
any time, either during or after your participation in the study, with no negative consequences. If
you withdraw from the study, your survey results will be destroyed.
Your Rights:
You can choose to participate in the study. If you do participate, you can withdraw from the
study at any time without consequences. You are not waiving any legal rights if you choose to
participate in the study. If you have questions about your rights as a participant of this study or if
you have concerns about the study and want to discuss those with someone other than Ellen Carr,
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you can contact the University of California Office of Research Protection, phone: xxxx address:
xxxxx
You may request a copy of the study’s final results by indicating your interest at the end of
this consent. And after this study if you are interested in being contacting by the investigator again
about a follow-up study about financial toxicity and cancer patients, please check the box below.
Investigator Identification:
Ellen Carr, RN, is the study investigator. If you have questions for Ellen, you can contact
her via this e-mail link: xxxxxx. You can also contact her at 619-922-3903.
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Participant Signature:
By clicking the accept key below, you are confirming that you have read this document, you
understand the purpose of the study and you have had the opportunity to ask questions about
proceeding to participate in the study.
Name
Signature (key click)

Date stamp:

e-mail address:
NOTE: Based on your clicking the accept key, Ellen Carr, the study’s investigator, will now contact
you by your e-mail above with a link to the study’s questionnaires. By completing the study’s
questionnaires, you have provided consent to participate in this study.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
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Investigator Signature:
By clicking the key below, I confirm that I have provided an explanation of the study to the
participant and have answered his/her questions. By the participant confirming that he/she has read
this document, the participant understands the purpose of the study and has had the opportunity to
ask questions, thereby giving asset/consent to proceed to participate in the study.
Name
Signature (key click)

Date stamp:

++++++
Further contact from Ellen Carr about study results or follow-up study:
 Please send a summary of the study results to:
Name
e-mail address
 I am not requesting a summary of the study results
 I am willing to be contacted by Ellen Carr, the study investigator, about a follow-up
study about financial toxicity and cancer.
Name
e-mail address
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Appendix E
Instrument # 1: Demographic Questionnaire
General
1) I am
 Female
 Male
2) I am
 < 50 years old
 50-64 years old
 >65 years old
3) My living status is
 Married
 Live with a domestic partner in the same household
 Live as a single
 Live in a community setting (i.e. with roommates)
4) Highest level of education
 < 12th Grade
 12th Grade
 Some college
 Completed college
 Some or complete graduate school
Cancer Diagnosis
1) I am diagnosed with cancer or malignancy
 Yes
 No
 Don’t know
2) If yes to #1 above, my cancer diagnosis is
(Open text; optional response)
3) Stage at Diagnosis
 Stage 1
 Stage 2
 Stage 3
 Stage 4
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4) Prescribed oral cancer therapy (drugs, dose, frequency)
(Open text)
5) Are you receiving your treatment given orally now?
 Yes
 No
6) Because of issues of cost or expense of the cancer therapy (given orally), when prescribed
the therapy I:
 Stayed on or completed the therapy
 Temporarily stopped taking the therapy
 Never started the therapy
7) Because of the cost or expense of the cancer therapy (given orally), did you decide to
stop taking any other prescribed medications or treatments for your other conditions? (i.e.
examples of other conditions, which you are receiving treatments: high blood pressure,
diabetes, high cholesterol, upset stomach, heart disease, arthritis, chronic pain, mental health
conditions, etc.)
 Yes
 No
8) For other prescribed medications you are taking (see #7), did you decide to take some of
those prescribed medications at their prescribed doses rather than your cancer therapy (given
orally) because of the cost or expense to take all your prescribed non-cancer and cancer
medications?
 Yes
 No
9) For other prescribed medications you are taking (see #7), did you decide to take lower or
less doses of medications rather than your cancer therapy (given orally) because of the cost
or expense to take all your prescribed non-cancer and cancer medications?
 Yes
 No
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Insurance
1) Do you have health insurance coverage?
 Yes
 No
2) If yes to #1, please check your current insurance coverage?
 Private Insurance (not Medicare)
 Medicare
 Medigap
 Medicare Part C (Advantage)
3) Do you have a Prescription Drug Plan?
 Yes
 No
4) If yes to #3, which plan?
 Private insurance prescription plan
 Medicare Part D

Finances
1) I am employed
 Fulltime
 Part-time (<20 hours/week)
 Not employed
2) Were you employed at the start of your treatment?
 Yes
 No
3) Does being in treatment for your cancer affect your ability to be employed?
 Yes
 No
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4) My income supports
 Myself only
 Myself and committed partner
 Myself, committed partner and others
5) During the last tax year, my gross income was
 < $50,000/year
 $50,000-$100,000/year
 $100,000-$200,000/year
 >$200,000/year
6) To cover the cost of my cancer treatment given orally, I am responsible to pay for:
 <20% of the cost
 20-50% of the cost
 50-100% of the cost
7) To cover the cost of my treatments, I received monetary help from pharmaceutical
companies, advocacy groups
 Yes
 No
8) If yes to #7, the monetary help I received per treatment was approximately:
 < 20%
 20-50%
 50-100%
 Don’t know
9) During my cancer treatment, other treatment-related expenses that I paid for out-of- pocket
include or included:
 transportation
 hotel costs
 lost wages
 child care
 over the counter medication
 Other (open text)
10) The monthly estimated out of pocket costs that I identified in #9 are:
 <$100/month
 $100-500/month
 500-1000/month
 >$1000/month
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Appendix F
Instrument #2: Comprehensive Score for Financial Toxicity (COST)

Source: deSouza J, Yap B, Wroblewski K, Blinder V, Araujo F, Hlubocky F, et al. Measuring
financial toxicity as a clinically relevant patient-reported outcome: The validation of the
comprehensive score for financial toxicity (COST). Cancer. 2017;123:476-84. (Used with
permission.)
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Appendix G
Instrument #3: National Comprehensive Cancer Network (NCCN) Distress Thermometer
(version 2.2018)

Source: NCCN: Retrieved from
https://www.nccn.org/patients/resources/life_with_cancer/pdf/nccn_distress_thermometer.pdf
(Used with permission: NCCN)

